
Author Index to Volumes 24-29

- Aamdahl S, 28:335
 Abe S, 29:191
 Abe T, 24:257; 25:375
 Adhvaryu SG, 27:33
 Adolph S, 26:235
 Ajmar F, 25:73; 25:265
 Akerman M, 25:55
 Alimena G, 26:5; 26:39;
 26:65; 27:21; 29:129
 Al Saadi A, 26:127
 Ambros P, 27:229; 29:315
 Amess J, 25:175
 Amess JAL, 28:287
 Amigo V, 26:171
 Andersson B, 27:349
 Andersson BS, 24:335
 Antony AC, 29:65
 Aoki N, 24:225
 Arai T, 24:359
 Arcese W, 26:5
 Archer SA, 24:271
 Arevalo M, 29:75
 Armitage JO, 25:219;
 27:335
 Arnold R, 26:51
 Arthur T, 27:345
 Arwert F, 25:37
 Atkin NB, 25:189; 26:355
 Aubert D, 28:119
 Audebert AA, 24:151
 Auerbach HE, 28:173
 Avanzi G, 29:57
 Avilés MJ, 29:75
 Ayuso C, 24:345
 Azar C, 25:367

 Babinska M, 25:123
 Babu A, 24:367
 Baccarani M, 26:65
 Badia L, 26:171; 28:367
 Baglin TP, 27:167
 Bain S, 25:165

 Baird M, 29:1
 Baker MC, 25:189; 26:355
 Bakhuis J, 27:21
 Bandini G, 26:5; 26:51
 Baranzelli MC, 25:371
 Barker PE, 25:379
 Barlogie B, 24:335;
 28:213
 Barry WE, 27:89
 Bartholdi MF, 27:273
 Bartnitzke S, 24:205;
 27:177
 Bartram CR, 26:235
 Baskin F, 28:163
 Bateman BJ, 25:219
 Battifora H, 29:303
 Bauters F, 24:355;
 25:103; 27:101;
 29:311
 Baylin SB, 25:27
 Becher R, 25:183; 26:51;
 26:217
 Behar C, 25:259
 Behm F, 24:87
 Behm FG, 27:251
 Beil B, 25:123
 Belch A, 27:135
 Bell DR, 25:141
 Bello C, 25:185
 Bello MJ, 25:355; 26:157;
 27:185; 28:187;
 29:75; 29:201;
 29:223; 29:323
 Bendix-Hansen K, 26:227
 Benet J, 29:91
 Benitez J, 24:345; 25:355;
 26:157; 26:199;
 27:185; 29:75; 29:201
 Benn P, 29:1
 Bennet K, 28:137
 Bennett DD, 25:97
 Bennett L, 29:1
 Beran M, 24:335, 27:349

 Bergan A, 28:335
 Berger C, 29:1
 Berger CL, 28:267
 Berger R, 25:303; 26:117;
 27:79; 28:119;
 28:261; 28:293; 29:9
 Berman M, 25:361
 Bernhardt B, 29:1
 Bernheim A, 25:303;
 27:79; 28:261;
 28:293; 29:9
 Bernstein R, 24:137;
 24:213
 Bertini M, 29:57
 Bertoglio MG, 27:45
 Bessho F, 29:175
 Bettecken T, 24:191
 Bhagat SG, 28:163
 Bhargava MK, 24:263
 Bielawiec M, 24:363
 Bigner DD, 24:163;
 29:165
 Bigner SH, 24:163;
 29:165
 Billström R, 24:159;
 25:161; 26:65; 27:1;
 28:191; 29:129
 Bjerrum I, 28:107
 Blaise AM, 25:259
 Blake M, 27:51; 27:63
 Blick M, 27:349
 Blin N, 25:285
 Block AW, 29:135
 Boccaccio P, 25:73
 Boehm TLJ, 28:327
 Boiron M, 28:293
 Boixados JR, 26:157
 Bomirski A, 25:123
 Bonfil X, 29:91
 Bonti GV, 27:367
 Boogaerts, 26:5; 26:51
 Bordoni S, 27:367
 Borrello MG, 27:45

- Böschén C, 24:205;
 27:177
 Bosly A, 28:113; 29:171
 Boswell HS, 29:65
 Bowcock AW, 24:137
 Boyle PD, 26:261
 Brasch J, 29:119
 Brasch JM, 25:131
 Brennan K, 27:161
 Bridge JA, 29:97
 Brieux de Salum S,
 25:309
 Brissaud P, 24:151
 Brodeur GM, 28:55
 Brodsky I, 26:15; 26:25
 Broegger A, 28:335
 Brøgger A, 24:327
 Brooks VP, 26:299
 Brothman AR, 26:287
 Brothman LJ, 26:287
 Brown JA, 27:251
 Brox LW, 27:135
 Bullerdiek J, 24:205;
 27:177
 Buonaguidi R, 27:145
 Burns D, 28:163
 Butler JJ, 24:7
 Butler MG, 24:129;
 28:253; 29:183
 Butti G, 27:145
 Buys CHCM, 27:361

 Caballin MR, 29:91
 Cabanillas F, 24:7
 Cacciapaglio B, 29:1
 Calabrese G, 29:261
 Calebretta B, 27:89
 Cao A, 27:219
 Caporaso N, 24:299
 Carbonell F, 26:5; 26:51;
 26:65
 Carloni I, 27:367
 Carritt B, 27:361
 Carroll AJ, 25:379
 Carroll PR, 26:253
 Carstens C, 25:285
 Casalone R, 27:145;
 29:253
 Cascos AS, 24:345;
 26:157
 Cassel C, 24:11
 Castoldi GL, 26:65; 26:75
 Castro R, 27:51; 27:63
 Cepulic M, 25:351;
 28:353
 Chaganti RSK, 26:253
 Chang C, 26:279
 Chattopadhyay SC,
 29:109
 Chen H, 28:301; 29:109
 Chen TR, 24:95; 27:125
 Chenevix-Trench G,
 27:191; 27:251
 Christiansen H, 26:235
 Christensen IJ, 27:225
 Clarke PT, 25:165
 Cline M, 29:303
 Coates PB, 25:165
 Cobcroft RG, 28:87
 Coleman M, 24:295; 29:1
 Collins D, 27:345
 Conde E, 25:185
 Conti AF, 27:261
 Cooper MD, 25:379
 Cork A, 24:7; 28:213
 Cosson A, 27:101
 Cournoyer D, 27:73
 Coviello DA, 25:73
 Cowan DH, 27:375
 Cowan JM, 27:251
 Cowell JK, 27:27
 Cram LS, 26:287; 27:273
 Criel A, 28:349
 Crilley P, 26:25
 Crossen PE, 28:93; 28:185
 Cuiffo BP, 25:1
 Cuneo A, 26:75
 Czepulkowski B, 25:175;
 28:287; 28:377

 Dal Cin P, 26:271;
 26:351; 26:377;
 28:343
 Dallapiccola B, 26:85
 Danes BS, 26:261
 Daniel M, 28:261; 28:293;
 29:9
 Darbyshire PJ, 28:377
 Darrah J, 24:11
 Dave BJ, 27:33
 Davis RM, 28:163
 Davoren B, 27:345
 De Braekeleer M, 24:177;
 27:135
 Debray J, 24:151
 Debruyne F, 29:23; 29:29
 de Campos JM, 25:355;
 26:157; 27:185;
 28:187; 29:201;
 29:223; 29:323
 De Cuia MR, 26:39; 27:21
 de Gramont A, 24:151
 de Koning H, 25:37
 de la Chapelle A, 25:87
 Delannoy A, 27:39
 De Laroque A, 27:371
 Della Porta G, 27:45
 Demaille MC, 25:371

 Deminatti M, 24:355;
 25:103; 25:371;
 27:101; 29:311
 den Dulk G, 24:231
 de Pargament MM,
 28:101
 DeRiese W, 26:369
 Derré J, 29:9
 Deschamps M, 29:183
 de Vinuesa ML, 28:101
 De Virgiliis S, 27:219
 Dewald GW, 27:73
 Di Bartolomeo P, 26:51
 Dieguez L, 26:171; 28:367
 Diez E, 28:119
 Diklic V, 28:183
 Di Lernia R, 27:299
 Dill FJ, 26:375
 Dissing J, 26:143
 Disteché CM, 25:271
 Diverio D, 26:39; 27:21;
 29:129
 Dizon D, 28:213
 Dolby TW, 24:17
 Doneda L, 27:261; 27:299
 Donselaar IG, 24:33
 Donti R, 27:367
 Dosik H, 24:295
 Doyen C, 28:113; 29:171
 Drabkowski D, 27:125
 Dragani A, 29:261
 Drahovsky D, 28:327
 Dray C, 24:151
 Dührsen C, 26:217
 Duncan AMV, 25:169
 Dutrillaux A, 25:7;
 29:289
 Dutrillaux B, 25:7; 29:289

 Eaves CJ, 24:1
 Edelson RL, 28:267
 Egozcue J, 29:91
 Eguchi M, 28:373
 Eisenberg A, 29:1
 Ekedahl C, 28:237
 Elfenbein IB, 27:89
 Emanuel BS, 25:369;
 26:181; 29:159
 Engert A, 26:363
 Engquist L, 27:1
 Estienne M, 29:311
 Etches WS, 24:177

 Faggionato F, 27:145
 Fair WR, 26:253
 Falchi AM, 27:219
 Falini B, 27:367
 Fan Y, 26:317; 29:135
 Farrer LA, 27:327

- Favrot M, 25:373
 Fayos JS, 26:199
 Fellin FM, 28:179
 Feminic-Kes R, 24:251;
 25:351; 28:353
 Fenaux P, 24:355;
 25:103; 29:311
 Fero ML, 26:245
 Ferrant A, 26:5; 26:51
 Ferstl G, 28:145
 Ferti-Passantonopoulou
 AD, 24:63; 27:289
 Filippetti A, 26:5; 26:51
 Fioritoni G, 29:261
 Fischer P, 28:145
 Fisher C, 26:179
 Fitchett M, 24:143
 Fitzgerald PH, 24:271
 Fitzgibbons RJ Jr, 28:245
 Flandrin G, 26:117;
 28:261; 28:293; 29:9
 Fodstad Ø, 24:327
 Fonatsch C, 26:363
 Fong C, 28:55
 Forni E, 29:253
 Francart H, 25:233
 Franchi PG, 29:261
 Franke F, 26:235
 Francke U, 27:251
 Franssila K, 25:87
 Fraser C, 24:1; 29:103
 Frassoni F, 26:5; 26:51
 Freireich EJ, 28:213
 Frejo CM, 26:199
 Freter CE, 29:155
 Fujii H, 25:375
 Fuscaldo KE, 26:25;
 26:65
 Gardner H, 27:229;
 28:145
 Gaeta J, 28:343
 Gahrton G, 26:5; 26:51
 Gale RP, 29:245
 Galvin GP, 27:167
 Ganser A, 28:327
 Garaedts J, 29:23
 Gardet P, 25:303
 Garijo J, 25:185
 Garson OM, 27:111
 Garvin AJ, 25:97
 Gastaldi R, 26:39
 Gazdar A, 29:155
 Gedde-Dahl T, 24:327;
 28:335
 Geelhoed GW, 24:11
 Geneix A, 27:371
 Genesca A, 29:91
 Geraci L, 29:261
 Geraedts J, 29:29
 Ghosh PK, 27:15
 Ghosh R, 27:15
 Giani S, 27:45
 Gibas L, 28:179
 Gibas Z, 25:21; 25:123;
 25:369
 Gibbons B, 25:175;
 28:287; 28:377
 Gilbert F, 24:75
 Gillespie DH, 26:15
 Giovinazzo G, 29:57
 Girodet J, 29:289
 Glick JH, 28:173
 Godwin JM, 28:93
 Gomis F, 28:367
 Goodacre A, 24:7; 24:335
 Goodfellow PJ, 27:327
 Goorha R, 27:251
 Gorman PA, 26:339
 Grabovskaya IL, 25:65
 Granata P, 27:145
 Greene MH, 24:299
 Griest A, 27:241
 Griffin CA, 25:369;
 26:181
 Griffiths MJ, 24:143
 Grossman A, 28:163
 Gualandri V, 27:261
 Guerrasio A, 29:57
 Gutterman J, 27:349
 Haas OA, 26:5; 26:51;
 27:229; 28:145;
 29:315
 Habibian R, 29:271
 Hagemeyer A, 27:21
 Halbrecht T, 27:171
 Han T, 24:109
 Hanada R, 28:373; 29:175
 Hansen HE, 26:143
 Harbott J, 26:235
 Harris MG, 28:87
 Hay RJ, 27:125
 Hayashi Y, 28:373;
 29:175
 Hayhoe FGJ, 28:145
 Hays T, 27:51; 27:63
 He XX, 27:135
 Heaton DC, 28:93
 Hecht BK, 26:95
 Hecht F, 24:189; 24:375;
 25:293; 26:65; 26:95;
 26:117; 26:175;
 28:189; 29:187
 Heckl W, 24:191
 Heerema N, 29:65
 Heerema NA, 27:241
 Heil G, 28:327
 Heim S, 24:159; 24:319;
 25:55; 28:137; 29:129
 Helsen C, 24:75
 Helson L, 24:75
 Henderson ES, 24:109
 Heuze F, 28:119
 Hill BT, 26:339
 Hill SM, 24:45
 Hirosawa S, 24:225
 Hirschfield L, 27:5
 Hoehn H, 24:191
 Hoelzer D, 28:327
 Hoffman R, 27:241; 29:65
 Holden JJA, 27:327;
 29:139
 Holldack J, 26:363
 Hollings, PE, 24:271
 Hölzel F, 28:201
 Hoo J, 29:319
 Hori T, 25:81
 Horiike S, 24:257
 Horita Y, 29:109
 Horn HL, 28:185
 Horsman DE, 26:375
 Hossfeld DK, 26:59;
 26:65
 Hough MR, 29:139
 House AK, 27:357
 Hovig E, 24:327
 Hsu TC, 28:5; 29:81
 Hu C, 26:279
 Hubbell HR, 24:17; 26:15
 Huben RP, 26:271
 Hulten MA, 24:45
 Hungerford J, 27:27
 Iacone A, 26:5
 Ichimaru M, 24:221;
 29:327
 Inazawa J, 24:257
 Iriondo A, 25:185
 Ishibe T, 25:317
 Ishihara T, 25:81
 Israel MA, 24:119
 Ito H, 26:191
 Itoyama T, 29:327
 Ivan D, 28:353
 Iwabuchi H, 29:331
 Jackson L, 28:179
 Jagelman DG, 27:319
 Jäger U, 29:315
 Jani KH, 27:33
 Jarzabek V, 25:293
 Jaspers NGJ, 24:33
 Jay M, 27:27
 Jean P, 28:229
 Jelbart ME, 26:165
 Jenks H, 28:277

- Jenkyn DJ, 26:327; 27:357
 Jhanwar S, 26:253
 Joenje H, 25:37
 Johansson B, 27:1; 28:137
 Johnson DR, 27:335
 Johnson S, 24:143
 Jouet JP, 24:355; 25:103;
 27:101; 29:311
 Joseph GM, 24:129;
 28:253
 Jotereau F, 28:119

 Kaczmarek L, 27:89
 Kakati 8, 26:271
 Kalousek DK, 24:1;
 26:375; 29:103
 Kamakura M, 25:253
 Kamihira S, 24:221
 Kamiyama R, 24:225
 Kaneko Y, 25:81; 26:309
 Kang L, 26:279
 Kant JA, 28:173
 Kao-Shan CS, 24:119
 Karpas A, 28:145
 Kastelan M, 24:251
 Kato A, 24:225
 Katz R, 24:7
 Keating A, 25:271
 Keating M, 28:213
 Keldsen N, 29:43
 Kendal WS, 29:81
 Kerndrup G, 26:227
 Kida M, 25:253
 Kidd JR, 27:327
 Kidd KK, 27:327
 Killough BW, 25:97
 Kimberling WJ, 27:161
 King CR, 27:345
 Kinniburgh AJ, 25:15;
 25:341; 26:105
 Kinzler KW, 29:165
 Kirkpatrick D, 28:155
 Kirsch IR, 26:95
 Kivi S, 28:77
 Klar D, 27:171
 Knapp W, 27:229
 Knerich R, 27:145
 Knospe WH, 25:361
 Knutsen T, 29:155
 Knuutila S, 25:87; 29:151
 Kobylka P, 25:329
 Koch H, 24:191
 Köhler J, 24:191
 Köller U, 27:229
 Konja J, 24:251; 25:351;
 28:353
 Kopelovich L, 28:245
 Kornmüller R, 27:229

 Kosmo MA, 29:245
 Kovacs G, 26:369; 28:363
 Kovanen PE, 29:151
 Kozlova TV, 25:65
 Kraemer PM, 26:287;
 27:273
 Kristoffersson U, 24:159;
 24:319; 25:55; 29:129
 Krulik M, 24:151
 Kubbies M, 24:191
 Kubota K, 24:359
 Kudo H, 24:225
 Kühn D, 25:183
 Kunzmann R, 28:201
 Kurzrock R, 27:349
 Kusak ME, 25:355;
 27:185; 28:187;
 29:201; 29:223;
 29:323
 Kuyl JM, 24:137

 Laarakkers L, 29:29
 Labal de Vinuesa M,
 25:47; 28:357
 LaGuette JG, 28:173
 Lai JL, 24:355; 25:103;
 25:371; 27:101;
 29:311
 Lambilliotte A, 27:101
 Lampert F, 26:235
 Lange BJ, 29:179
 Lanspa SJ, 28:245
 Lanza F, 26:75
 Larizza L, 27:261; 27:299
 Larrackers L, 29:23
 Larripa I, 25:47; 28:101;
 28:113; 28:357
 Larsen JK, 27:225
 Latimer F, 26:127
 Lauer RC, 29:65
 Le Coniat M, 25:303; 29:9
 Lemieux N, 28:229
 Le Pelley P, 24:355
 Leung J, 28:155
 Lewis JP, 28:277
 Li FP, 24:11
 Li P, 26:317
 Li Y, 26:379
 Lier ME, 28:335
 Ligler FS, 26:25
 Limon J, 25:123; 26:271;
 28:343
 Lin CC, 24:177; 27:135
 Lin K, 29:331
 Linder J, 27:335
 Ling V, 25:141
 Lister TA, 25:175; 28:287
 Lizard-Nacol S, 25:373

 Lombard M, 25:7
 London B, 27:375
 Lothe RA, 28:335
 Louwagie A, 25:233;
 27:39; 28:349
 Lukasova M, 25:329
 Lukeis R, 27:111
 Lynch HT, 25:247;
 27:161; 28:245
 Lynch JF, 25:247; 27:161;
 28:245

 Macdougall LG, 24:213
 Macera MJ, 24:367
 Macrae FA, 27:111
 Macy M, 27:125
 Madercic M, 26:127
 Madvedeva NV, 25:65
 Maeda S, 28:301; 29:109
 Magnani I, 27:299
 Majdic O, 27:229
 Makarkina GN, 25:65
 Malay MAL, 27:357
 Malet P, 27:371
 Mamaev NN, 25:65
 Mamaeva S, 28:311
 Mamaeva SE, 25:65
 Mandahl N, 24:159;
 24:319; 25:55;
 28:137; 29:129
 Manning J, 24:7
 Manolov G, 28:145
 Manolova Y, 28:145
 Marcus JN, 28:245
 Mark J, 24:163; 28:237;
 29:165
 Markkanen A, 25:87
 Marynets OV, 25:65
 Maseki N, 26:309
 Masuda H, 29:303
 Mayer M, 26:299
 McCarthy CMT, 28:87
 McCartney AJ, 26:327
 McCredie KB, 24:335;
 28:213
 Mecucci C, 25:233; 26:5;
 26:51; 27:39; 28:113;
 28:349; 29:171
 Meese E, 25:285
 Meggyessy V, 24:185
 Mehes K, 24:185
 Meisner LF, 29:239
 Melamed MR, 26:261
 Mendelow M, 24:137
 Meriggi F, 29:253
 Mertens F, 27:1; 28:137
 Michael S, 26:299
 Michalova K, 25:329

- Michaux J, 27:39; 29:171
 Michaux JL, 25:233; 26:5;
 26:51
 Micic M, 28:183
 Micic S, 28:183
 Midro AT, 24:363
 Mierzewski P, 25:123
 Mikelsaar AV, 28:77
 Milasin J, 28:183
 Miller KB, 25:1; 26:105;
 26:191
 Milligan DW, 27:215
 Minamihisamatsu M,
 25:81
 Minowada J, 25:341
 Miro R, 29:91
 Misawa S, 24:257;
 25:375; 28:127
 Mise K, 29:191
 Miser J, 24:119
 Mitelman F, 24:159;
 24:315; 24:319;
 25:55; 25:161; 26:65;
 27:1; 28:137; 28:191;
 29:129
 Mitsuyasu RT, 29:245
 Mitter NS, 25:187; 26:209
 Miura O, 24:225
 Miura Y, 29:191
 Montefusco E, 27:21
 Mooibroek H, 27:361
 Moreno S, 25:355;
 28:187; 29:223;
 29:323
 Morgan R, 25:293; 26:117
 Morgan RJ, 27:215
 Morgan WF, 26:245
 Moriyama-Gonda N,
 25:317
 Morris CM, 24:271
 Morse HG, 27:51; 27:63
 Mudry de Pargament M,
 28:357
 Mugneret F, 25:373
 Muhlbaier LW, 29:165
 Muleris M, 25:7; 29:289
 Müller-Brechlin R,
 25:285; 26:369;
 28:363
 Mulvihill JJ, 24:299
 Murakami N, 24:225
 Murao S, 20:109
 Murata M, 25:81
 Murohashi I, 24:225
 Murty VVS, 26:253

 Nacheva E, 28:145
 Nahreini P, 29:65
 Nakamura H, 24:221;
 29:327
 Nakazawa S, 28:373
 Nakic M, 24:251; 25:351;
 28:353
 Nanfro JJ, 29:155
 Nanni M, 26:39; 29:129
 Narni F, 27:89
 Navarro J, 29:91
 Neff JR, 29:97
 Nelkin BD, 25:27
 Neretto G, 28:181
 Neuwirt J, 25:329
 Nieuwint AWM, 25:37
 Niitsu N, 28:373
 Nilsson P, 25:161; 28:191
 Nilsson PG, 24:315
 Nishida K, 25:375
 Nishino K, 24:221
 Nowak MJ, 28:155
 Noel P, 27:73
 Nowell PC, 24:371;
 28:173; 29:159
 Nucaro AL, 27:219

 O'Brien S, 29:319
 Ochoa-Noguera ME,
 28:293; 29:9
 Odom LF, 27:51; 27:63
 Ohde S, 28:373
 Ohsumi Y, 25:317
 Ohyashiki JH, 24:109;
 24:281; 25:1; 25:15;
 25:341; 26:105;
 26:191; 26:213;
 29:331
 Ohyashiki K, 24:109;
 24:281; 25:1; 25:15;
 25:341; 26:105;
 26:191; 26:213;
 29:331
 Olsson H, 25:55
 Oostra AB, 25:37
 Orofino MG, 27:219
 Orts MA, 26:171
 Oscier DG, 24:143
 Osinga J, 27:361
 Otaki K, 24:281
 Oyakawa Y, 24:221

 Pabinger I, 29:315
 Pacot A, 25:303; 29:9
 Paietta E, 25:227; 25:367
 Palka G, 26:5; 26:51;
 29:261
 Palmer CG, 27:241
 Panani AD, 24:63; 27:289
 Panarella C, 25:73

 Pantzar JT, 26:375
 Papa G, 26:5
 Papenhausen P, 25:227;
 25:367
 Parmentier C, 25:303
 Partington MW, 25:169
 Pasquali F, 29:253
 Pathak S, 24:7; 24:335
 Pauwels R, 29:23; 29:29
 Pedersen B, 26:227
 Pedersen-Bjergaard J,
 29:43
 Peetre C, 24:315
 Pegoraro L, 29:57
 Perissel B, 27:371
 Peterson W Jr, 27:125
 Petkovic I, 24:251;
 25:351; 28:353
 Philip P, 28:107; 29:43
 Philip T, 25:373
 Phillips JA III, 24:129;
 29:183
 Pickle LW, 24:299
 Pierotti M, 27:45
 Pigeon F, 25:259
 Pignon B, 25:259
 Pilotti S, 27:45
 Pinkerton PH, 27:375
 Pinto MR, 24:137; 24:213
 Pittman S, 26:165
 Pollak C, 26:5; 26:51
 Pollock A, 27:167
 Pollock E, 27:135
 Ponzio G, 28:181
 Postmus PE, 27:361
 Potluri VR, 24:75
 Poulsen H, 26:143
 Pressler T, 28:107
 Preisler HD, 24:281;
 25:15; 26:105; 26:213
 Prescher G, 25:183
 Prieto F, 26:171; 28:367
 Purtilo D, 27:335; 24:11

 Quinn LA, 24:17

 Raabe G, 27:177
 Rabinovitch PS, 24:191
 Raghavan D, 26:165
 Ragsdale ST, 24:87
 Raimondi SC, 24:87
 Rajic L, 24:251; 25:351;
 28:353
 Rames LJ, 28:253
 Ramos C, 24:345; 26:199;
 29:201
 Ranni NS, 25:309; 28:101
 Ranstam J, 25:55

- Rao U, 26:271
 Raptis SA, 24:63
 Rasi V, 25:87
 Raskind WH, 25:271
 Ray FA, 27:273
 Raza A, 24:181; 24:281;
 25:15; 26:105;
 26:213; 27:269;
 27:311; 29:135
 Reeves BR, 26:179;
 26:185
 Rege-Cambrin G, 25:233;
 28:181
 Reimer DL, 29:139
 Reiss R, 27:171
 Reiter A, 26:235
 Repaske DR, 24:129
 Resegotti L, 29:57
 Reuter V, 26:253
 Rey JA, 25:355; 26:157;
 27:185; 28:187;
 29:75; 29:201;
 29:223; 29:323
 Ricci P, 26:5; 26:51
 Richard C, 25:185
 Richer C, 28:229
 Ringborg Y, 26:261
 Riordan JR, 25:141
 Ritter HL Jr, 24:243
 Rivera G, 24:87
 Rizzi R, 27:299
 Robbins T, 26:127
 Roberts C, 24:231; 29:119
 Roberts CG, 27:9
 Roberts M, 25:227
 Robinson A, 27:51; 27:63
 Rodgers CS, 24:45
 Roloff B, 29:239
 Romero P, 27:349
 Rööser B, 24:319
 Roozendaal KJ, 25:37
 Rosen N, 25:227
 Rosenberg RN, 28:163
 Rosendorff J, 24:137
 Rosetti A, 26:5; 26:51;
 27:367
 Rosman I, 24:271
 Ross FM, 25:109
 Rosso A, 29:57
 Rosti G, 26:5; 26:51;
 26:65
 Rowe J, 26:105
 Roza-de Jongh EJM, 24:33
 Rubin SC, 25:21
 Rudolph B, 26:235
 Rümke P, 24:33
 Russell P, 24:231
 Russell PJ, 26:165
 Rutland P, 27:27
 Ruutu T, 25:87
 Ryan DH, 26:191
 Rydholm A, 24:319;
 28:137
 Sadamori N, 24:221;
 29:327
 Saglio G, 29:57
 Sailer M, 27:311
 Sait SNJ, 24:181; 26:117;
 26:351; 27:269;
 27:311; 29:135
 Sakurai M, 26:309
 Salk D, 24:191
 Salmon R, 29:289
 Samuel I, 29:319
 Sandberg AA, 24:109;
 24:181; 24:281; 25:1;
 25:15; 25:123;
 25:293; 25:341; 26:1;
 26:65; 26:105;
 26:117; 26:175;
 26:177; 26:191;
 26:213; 26:271;
 26:351; 26:377;
 27:181; 27:269; 28:1;
 28:343; 29:135
 Sanger WG, 25:219;
 27:335; 29:97
 Sarasa JL, 26:157
 Sargent LM, 29:239
 Sasagawa I, 24:221;
 29:327
 Sasaki M, 29:191
 Sato Y, 29:191
 Savary J, 24:355; 25:103;
 25:371; 27:101;
 29:311
 Savelyeva L, 28:311
 Sawicka A, 24:363
 Scheerer P, 25:293
 Schimke RN, 27:345
 Schmeizer T, 26:5
 Schmidt GG, 25:183
 Schmidt MA, 27:73
 Schorin M, 28:155
 Schrier S, 26:117
 Schumer J, 29:135
 Scott DC, 28:87
 Seabright M, 24:143
 Seikevych IA, 26:299
 Senn JS, 27:375
 Sessarego M, 25:73;
 25:265; 26:5; 26:51
 Shabtai F, 27:171
 Shaffer B, 29:97
 Shapiro PE, 28:267
 Sheer D, 26:339
 Sheppard DM, 26:339
 Sherrington P, 28:145
 Shetty NJ, 24:263
 Shirakura T, 24:359
 Shisa H, 29:109
 Shtalrid M, 27:349
 Sigaux F, 28:293; 29:9
 Siver RT, 24:295; 29:1
 Silverstein M, 29:1
 Simi P, 27:145
 Simpson E, 28:287
 Simpson JL, 25:191
 Simpson NE, 27:327
 Singer JW, 25:271
 Sirinelli A, 24:151
 Slavutsky I, 25:47;
 25:309; 28:101;
 28:357
 Smadja N, 24:151
 Smeets W, 29:23; 29:29
 Smith A, 24:231
 Smith S, 26:179; 26:185
 Smyth DR, 25:131
 Sneige N, 24:7
 Snyderman M, 29:135
 Solero L, 27:145
 Soper L, 29:1
 Soudek D, 25:169
 Soukup SW, 29:179
 Sozzi G, 27:45
 Spadano A, 29:261
 Sparkes RS, 29:245
 Speaks SL, 27:335
 Spector I, 24:213
 Spielvogel A, 25:367
 Spinner NB, 29:159
 Sreekantaiah C, 24:263
 Srivastava A, 29:65
 Staal SP, 28:127
 Stamberg J, 27:5
 Stanley WS, 25:97
 Stass S, 28:213
 Stelmach T, 24:371;
 28:173
 Stenwig AE, 28:335
 Sternberg A, 27:171
 St. John DJB, 27:111
 Stockdill G, 25:109
 Stollmann B, 26:363
 Strand R, 28:155
 Strayer DR, 26:15
 Stuppia L, 29:261
 Su Y, 26:279
 Sugita K, 28:373
 Sugiyama T, 28:301;
 29:109
 Sullivan LD, 29:103

- Surti U, 29:271
 Swansbury GJ, 28:375
 Szűcs S, 26:369; 28:363
 Szüle E, 24:185

 Tagawa M, 24:221;
 29:327
 Takagi T, 25:81
 Takahashi E, 25:81
 Takahashi R, 28:301;
 29:109
 Takai S, 24:225
 Takeda T, 24:359
 Takeuchi J, 24:109
 Takino T, 24:257; 25:375
 Talpaz M, 27:349
 Tanaka K, 25:27
 Taniwaki M, 24:257;
 25:375
 Tarantino E, 27:145
 Tassinari A, 26:65
 Tattersall MHN, 24:231;
 27:9; 29:119
 Templado C, 29:91
 Testa JR, 25:27; 28:127
 Testoni N, 26:5; 26:51;
 26:65; 28:113
 Teyssier J, 25:179; 25:259
 Thay TY, 24:177
 Thiele CJ, 24:119
 Thomas S, 24:295
 Thurber WA, 24:11
 Tiefenbach A, 24:251;
 25:351; 28:353
 Toledo C, 26:199
 Tommerup N, 27:225
 Tomonaga M, 24:221
 Tonomura A, 24:225
 Törzsök F, 24:185
 Toyama K, 29:331
 Traganos F, 26:261
 Travade P, 27:371
 Trent JM, 25:141; 26:187;
 28:3
 Tricot G, 25:233; 27:39;
 27:241
 Trivedi AH, 27:33
 Trujillo J, 24:7; 27:349
 Trujillo JM, 28:213
 Tsai S, 24:299
 Tucker J, 25:175; 28:287
 Tully SM, 28:93

 Tura A, 26:65
 Tura S, 26:3; 26:5; 26:51
 Turc-Carel C, 25:373;
 26:177; 26:377
 Turchini MF, 27:371
 Tygstrup I, 27:107
 Tytgot H, 28:113

 Uehara M, 25:253
 Usui T, 25:317


 Valcarcel E, 24:345;
 27:185
 Valensi F, 28:293; 29:9
 Valenti S, 26:5; 26:51
 Van Den Berghe H,
 25:233; 26:5; 26:51;
 26:175; 27:39; 28:49;
 28:113; 28:349;
 29:171
 van der Kamp AWM,
 24:33
 van Haften-Day C, 24:231
 van Hemel JO, 24:33
 Van Hoof A, 28:349
 Van Hove W, 25:233
 Vannais D, 27:51; 27:63
 Van Orshoven A, 27:39
 Van Velzen-Tillemans
 JTM, 24:33
 Vecchione D, 25:303;
 29:9
 Vejerslev LO, 26:143;
 27:225
 Verma RS, 24:295; 24:367
 Vermaelen K, 27:39
 Verp MS, 25:191
 Vielh P, 29:289
 Vogelstein B, 29:165
 Volk C, 25:373
 Vonderheid EC, 27:89;
 29:159
 Vlachos JD, 24:63
 Vyas RC, 27:33

 Walen KH, 25:149
 Walling P, 27:277
 Wang N, 28:155
 Wang R, 29:81
 Wang-Wuu S, 26:279;
 29:179

 Warburton D, 28:267
 Ward B, 26:339
 Warmoth LA, 28:163
 Warrior RP, 28:155
 Wass J, 26:165
 Wechsler A, 25:309
 Weiden PL, 24:243
 Weisenburger D, 27:335
 Weiskopf RW, 26:209
 Welborn JL, 28:277
 Wells IC, 25:247
 Westin EH, 27:251
 Whang-Peng J, 24:119;
 29:155
 Wheeler K, 28:377
 Whelan RDH, 26:339
 White BN, 27:327; 29:139
 Whitehead RH, 27:111;
 27:357
 Whitmore WF, 26:253
 Wiernik PH, 25:227;
 25:367
 Willard HF, 25:141
 Willen H, 24:319; 28:137
 Williams DL, 24:87
 Williams J, 27:215
 Winberg JO, 24:327
 Witkowski CM, 26:187
 Wojtukiewicz M, 24:363
 Wong AJ, 29:165
 Wong L, 26:179; 26:185
 Wu K, 26:279

 Yamada Y, 24:221
 Yamamoto K, 28:373;
 29:175
 Yang C, 26:379
 Yang JPS, 24:11
 Yao E, 24:221; 29:327
 Yokota J, 29:303
 Yoshida MA, 24:281
 Young BD, 28:287

 Zaccaria A, 26:3; 26:5;
 26:51; 26:65
 Zafrani B, 29:289
 Zandecki M, 27:101;
 29:311
 Zander A, 24:7
 Zang KD, 25:285
 Zubizarreta A, 25:185



Subject Index to Volumes 24-29

- Acquired idiopathic sideroblastic anemia (AISA)
i(7q), 25:49
- Acute leukemia
in vitro differentiation, 28:327
T-cell receptor, 28:327
with t(4;17), T-lymphoid and myeloid surface antigens, 28:327
- Acute lymphoblastic leukemia (ALL)
bone marrow transplantation, 26:51
cell line, 25:379
chromosome studies, 26:51, 59
constitutional chromosome changes, 24:345
constitutional r(21), 27:219
DNA measurements in adult, 28:213
in Down syndrome, 28:155
NALM-cell lines, 25:341
NOR in marrow cells, 25:65
pre-B with t(1;19), 25:379
t(1;19) in pre-B, 25:379
t(8;12;14) in Burkitt-type ALL, 28:145
telomeric association, 24:87
tetraploidy, 29:129
1q trisomy, 24:87, 251
1q+ in ALL, 24:251
5q- and *fms* gene, 25:341
+9 constitutional in, 24:345
- Acute lymphocytic leukemia; see Acute lymphoblastic leukemia (ALL)
- Acute monoblastic leukemia (AMoL)
Auer rods and cytogenetics, 28:191
chromosome changes with inv(16), 26:309
DNA measurements in adult, 28:201
inv(16) in M5b, 26:309
t(8;16) in M5a, 24:213
11q13 in, 26:351
- Acute myeloblastic leukemia (AML); see also Acute nonlymphocytic leukemia
Auer rods and chromosomes, 28:191
chromosome changes in, 25:329
constitutional t(3;6), 25:87
DNA measurements in adult, 28:213
i(7q), 24:49
i(11q), 24:49
i(17q) in M2, 24:315, 25:49
M2 with 9q-, 24:177
Sweet's syndrome with t(3;5), 28:87
t(6;9) in, 26:363
t(7;11) and c-Ha-ras-1, 29:199
with t(8;16), DIC and bone marrow necrosis, 24:243
XYY in M2, 24:363
5q- in, 26:199
- Acute myeloid leukemia; see Acute nonlymphocytic leukemia
- Acute myelomonocytic leukemia (AMMoL)
Auer rods and cytogenetics, 28:191
chromosome changes in, 25:329
DNA measurements in adult, 28:201
double minutes and normal karyotype, 25:1
fragile site on #16, 25:81
i(17q), 25:49
in patient with familial t(6;16), 29:159
inv(16) and other changes, 26:309
inv(16) in eosinophils, 29:327
inv(16) in XY/XYY male, 29:331
inv(16) (p13q22), fra(16)(q22), 25:81
M4 with t(1;11), 24:181
t(7;11), 26:191
t(8;16) in, 27:101
11p changes, 28:287
11q13 in, 26:351
- Acute nonlymphocytic leukemia (ANLL)
AML with 9q-, 24:177
AMMoL with t(1;11), 24:181
AMoL with t(8;16), 24:213
Auer rods and cytogenetics, 28:191
bone marrow transplantation, 26:51
c-mos studies, 24:137
cell kinetics, 28:357
changes in Chinese patients, 26:379
chromosome changes in, 25:329; 26:51, 28:293; 29:9
chromosome changes in secondary ANLL, 29:43

- (ANLL) con't
 constitutional chromosome disorder, 24:345
 DNA measurements in adult, 28:201
 double minute chromosome, 25:1
 Down syndrome, 28:155
 i(17q) in M2, 24:315
 inv(12) constitutional in, 24:345
 inv(16) in t-ANLL, 27:167
 NOR in marrow cells, 25:65
 prognostic significance of cytogenetic findings, 28:293
 rheumatoid arthritis, 25:161
 ring (21) constitutional in, 24:345
 secondary, 26:65; 29:43
 t(1;7), a correction, 25:187
 t(3;5), 28:261
 t(6;9) in, 26:363
 t(8;16) in, 27:101
 t(8;16) in AML with DIC and marrow necrosis, 24:243
 t(8;21) in AML, 24:137
 t-ANLL (therapy related), 27:167
 therapy related (t-ANLL), 27:167
 translocations and deletions involving 21q in secondary ANLL, 29:43
 trisomy 21 (+ 21) in, 24:345
 + 4, 26:117, 171, 175
 5q- in, 26:199
 11p changes, 28:287
 11q13 in, 26:351
 21q breakpoint in secondary ANLL, 29:43
- Acute promyelocytic leukemia (APL)
 Auer rods and cytogenetics, 28:191
 DNA measurements in adult, 28:201
 in CML, 28:349
 t(15;17) and t(2;17;15) in a case, 28:107
 t(X;15) in, 29:65
 variant t(15;17), 28:349
- Adenoma(s)
 marker similar to one in endometrial cancer, 27:177
 pleomorphic, 28:237
 pleomorphic with t(3;8;8), 27:177
- Adipose tissue tumors
 rings in lipogenic tumors, 24:319
- Adrenocortical
 carcinoma, 26:271; 28:343
 t(4;11) in, 28:343
- AIDS
 + 12 in Burkitt-like lymphoma, 29:245
- Amplification
 c-myc in human leukemia sublines, 28:127
 in gliomas, 29:165
 in HSR, 29:139
- Anemia
 aplastic, 24:345
 constitutional chromosome changes, 24:345
 Fanconi, 25:37
 refractory and double minutes, 28:367
 refractory with - 2, 28:367
 refractory with 5q-, 24:159
 refractory with excess of blasts, 25:175
 t(6;9), 29:135
 5q- in refractory anemia, 28:375
 + 14 in RAEB, 29:325
- Animal cells
 Abelson virus induced, 28:119
 Chinese hamster, 27:273
 karyotypes in Chinese hamster cells, 27:273
 mouse leukemia cells, 29:109
 mouse lymphoma, 28:119
 neoplastic evolution, 27:273
- Astrocytoma
 chromosomal patterns, 29:201
- Ataxia telangiectasia
 cancer proneness, 26:85
 CLL in, 26:217
 cytogenetics, 26:85, 217
 T-cell CLL, 26:217
- Auer rods
 AML and, 28:191
 ANLL and, 28:191
- B-cells(s)
 CLL, 24:145; 25:109; 26:75
 in PHA-stimulated lymphocytes, 29:151
 lymphoma, 24:271
 mitogens, 24:109, 25:109
 molecular studies, 27:251
 polyclonal activators, 24:109
 pre-B ALL, 26:379
 TPA as mitogen, 26:109
- bcr (Breakpoint cluster region)
 in CML, 26:105; 27:349; 29:1, 57
 in CML cell line K562, 26:105
 in CML cell lines, 25:271; 26:105; 27:349
 in masked Ph, 25:15, 105
 in variant Ph, 26:105
 rearrangements in CML, 25:15, 105; 29:1, 57
 studies in blastic phase, 29:57
 value of analysis in CML, 29:1
- Bladder
 chromosome changes, 29:29
 familial cancer, 27:161
 method for analysis of biopsies, 29:103
 method for cytogenetic analysis, 29:23, 103
 ring chromosomes, 28:183
 tumors, embryonal origin, 24:189

- Blast crisis
 APL with variant t(15;17) in, 28:349
 bcr studies, 29:57
 double minutes in CML, 25:253
 in thrombocythemia, 25:227
 karyotypes in, 26:39
 lymphoid in Ph-positive
 thrombocythemia, 25:227
 masked Ph in, 26:42
 morphology of cells, 26:42
 Ph and 9q+ duplication, 29:57
 promyelocytic with t(15;17), 29:311
 rings in CML, 25:253
 surface markers, 26:25
- Bloom syndrome
 cancer proneness, 26:85
 cell lines, 26:287
 cytogenetics, 26:85
 DMS in cell line, 26:287
 fibroblast cultures, 26:287
 oncogene expression, 26:287
- Bone marrow
 BrdU and cell synchronization, 28:229
 changes in ANLL, 25:329
 changes in CLL, 25:109
 changes in PV, 25:233
 disease with t(11;22) and other changes,
 28:277
 methodology, 28:229
 necrosis with DIC and t(8;16) in AML,
 24:243
 NOR in cells, 25:65
 transplantation in ALL, 26:51
 transplantation in ANLL, 26:51
 transplantation in CML, 26:5
- Brain tumors
 astrocytoma, 29:201
 C-bands in patients, 27:185
 cell lines, 24:163
 clinical significance of chromosome
 changes, 26:127
 cytogenetics of, 24:163; 26:127
 gene amplification in gliomas, 29:165
 glioblastoma cell line and oncogenes,
 25:285
 gliomas, 24:163; 29:223
 meningioma, 26:127
 metastatic lung tumors with 3p-,
 25:355
 + 7 in gliomas, 29:323
- Breakpoints
 in rectal cancer, 25:7
 3p21 and 3q25 in CML, 27:371
 13q in retinoblastoma, 27:27
- Breast cancer
 chromosome breakage, 24:52
 chromosome changes in 24:45; 27:289
 cytogenetics of, 24:52
 double minutes in, 24:52
 HSR in, 24:52
 karyotypes in, 24:52; 27:289
 oncogenes in glioblastoma cell line,
 25:285
 PCC, 24:52
 rings, 24:52
 triploid/tetraploid tumors, 24:45
 #8 and #13 in, 24:45
- Brunner tumor
 in gonadal dysgenesis, 25:191
- Burkitt
 translocation t(2;8), 24:225
 type ALL with t(8;12;14), 28:145
- Cancer cytogenetics
 background, 28:5; 29:198
 historical, 28:5
 hypotheses, 28:5
 origin, 29:187
- Carcinoid
 cell line, 24:17
 COLO 320 cell line, 24:17
 double minutes, 24:17
 non-c-myc DNA, 24:17
 of colon, 24:17
- C-band(s)
 heteromorphism, 27:33
 in breast cancer, 28:77
 in cancer families, 27:261
 in CML cases, 27:33
 in multiple myeloma, 28:101
 in nervous system tumors, 27:185
 in nonpolyposis colon cancer syndrome,
 27:111
 in ovarian cancer, 28:77
 mosaicism of chromosome 1 in cancer
 families, 27:261
- Cell kinetics
 in hemotologic disorders, 28:357
- Cell line(s)
 ALL, 25:379
 amniocyte, 25:149
 Bloom syndrome fibroblasts, 26:287
 Chinese hamster, 27:273
 CML, 24:335; 25:271
 COLO 320, 24:17
 colon cancer, 27:111, 125, 357
 colon carcinoid, 24:17
 DMBA-induced, 28:301
 dysplastic nevus syndrome, 24:33
 erythroleukemia (D5A1) with
 chromosome marker, 28:301
 gliomas, 24:163
 HeLa-76, 28:311
 hepatoma, 26:279
 HL-60 cells, 27:311
 human leukemia (HL-60), 28:127

- Cell line(s) con't
 human T-cell leukemia, 29:119
 K562 (CML), 26:105
 lung adenocarcinoma, 26:317
 mouse (LM, A9, Rag), 24:95
 mouse melanoma, 29:81
 near-haploid and Ph-positive, 24:335
 neuroectodermal tumor, 24:75
 osteosarcoma with #13 anomaly, 24:327
 ovarian cancer, 24:231; 26:339; 28:201
 plasma cell, 27:135
 primitive neuroectodermal tumor, 24:75
 prostate cancer, 26:165
 rRNA amplified in T-cell line, 28:119
 thyroid cancer, 27:27
 transformed by SV40, 25:149
 WiDr and HT-29 colon cancer, 27:125
- Cervical cancer
 PCC in, 24:263
- Chromosomal location
 c-met, 26:187
 cystic fibrosis gene, 26:187
 mdrl gene, 26:187
 P-glycoprotein locus on 7q36, 25:141; 26:187
 7q36 locus for P-glycoprotein, 25:141
- Chromosome
 #1 in ALL, 24:87
 #1 in endometrial cancer, 25:21
 #1 in Ewing sarcoma, 25:97
 #1 in gastric cancer, 24:63
 #1 in neuroectodermal tumor cell line, 24:75
 #1 in ovarian cancer cell lines, 24:231
 #1 in secondary lymphoma, 24:7
 #1, #3 and #6 in ovarian cancer cell line, 26:339
 #2 in MDS, 26:227
 #3 in hairy cell leukemia, 24:109
 #3 in lung cancer, 25:355; 27:361
 #3 in lymphoma, 25:55
 #3 in renal cancer, 26:253
 #4 in ANLL, 26:117, 171, 175
 #5 in preleukemia and leukemia, 26:199
 #5 in PV, 25:233
 #6 in ovarian cancer cell lines, 24:231
 #7 in gastric cancer, 24:63
 #7 in gliomas, 29:323
 #7 in hematologic disorders, 25:47
 #7 in lymphoma, 25:55
 #7 in MPD, 26:209
 #7 in PV, 25:233
 #7, #1 and #9 in myeloproliferative disorders, 24:151
 #8 in ANLL, 27:269
 #8 in breast cancer, 24:45
 #8 in gastric cancer, 24:63
 #8 in MDS, 26:227
 #8 in mixed salivary gland tumors, 24:205
 #9 in gastric cancer, 24:63
 #9 in MDS, 26:227
 #10 in endometrial cancer, 25:21
 #10 in hairy cell leukemia, 24:109
 #11 and iron stores in MDS, 24:39
 #11 in ANLL, 26:351; 28:287
 #11 in hematologic disorders, 25:47; 28:287
 #11 in secondary lymphoma, 24:7
 #12 in CLL, 25:109; 26:75; 28:93
 #12 in lymphoma, 25:55; 29:245
 #12 in ovarian tumor, 26:355
 #13 in breast cancer, 24:45
 #13 in hematologic disorders, 24:143
 #13 in osteosarcoma cell line, 24:327
 #13 in PV, 25:233
 #14 in AT with T-CLL, 26:217
 #14 in RAEB, 29:315
 #16 in AMMoL (M4), 24:251
 #17 and pseudo-Pelger-Huet anomaly, 25:265
 #17 in CML, 25:265
 #17 in hairy cell leukemia, 24:109
 #17 in hematologic disorders, 25:47
 #17 in MDS, 26:227
 #20 in MEN-II, 24:129; 27:327; 28:253
 #20 in PV, 25:233
 #21 in hematologic disorders, 25:47
 #21 in secondary lymphoma, 24:7
 #22 in meningioma, 26:127; 27:145
- Chromosome breakage; see also
 Chromosome instability disorders
 in amniocyte cell lines, 25:149
 in breast cancer, 24:52
 in Fanconi anemia, 25:37
- Chromosome changes
 constitutional in hematopoietic disorders, 24:345
 deletions in MDS, 26:227
 dup(11q) partial in secondary lymphoma, 24:7
 dysplastic nevus syndrome (DNS), 24:33
 i(17q) in AML, 24:315
 in a transplantable melanoma, 25:123
 in adrenal cancer, 26:271
 in ALL, 24:87; 26:59
 in AML, 25:329; 28:191
 in AMMoL (M4), 24:257
 In ANLL, 25:329; 26:351, 269; 28:191, 293
 in astrocytomas, 29:201
 in bladder cancer, 29:29
 in blast crisis of CML, 26:39

- in breast cancer, 24:45; 27:289
- in CLL, 24:143; 25:109; 26:75; 28:93
- in CML, 24:143, 281; 25:75, 267, 329; 26:25, 39
- in colorectal tumors, 29:289
- in gastric cancer, 24:63
- in gliomas, 24:163; 29:223
- in hairy cell leukemia, 24:109
- in HeLa cell line, 28:311
- in hematologic disorders, 24:143
- in lymphocytes of thyroid cancer patients, 25:303
- in lymphoma, 24:271; 25:223; 27:335
- in MDS, 24:143; 25:329; 26:227; 27:39
- in megakaryoblastic leukemia, 25:259
- in MEN-II, 24:129; 27:327; 28:253
- in meningioma, 26:127; 27:145
- in mesothelioma, 29:75
- in MPD, 24:143, 151; 25:329
- in neuroblastoma, 26:235
- in neuroectodermal tumor cell line, 24:75
- in neurofibroma, 26:157
- in osteosarcoma cell line, 24:327
- in ovarian cancer cell lines, 24:231; 26:339
- in ovarian tumors, 26:327, 355
- in pancreatic cancer, 29:253
- in peripheral neuroepithelioma, 24:119
- in PNH, 25:259
- in prostate cancer, 26:165
- in renal cancer, 26:253
- in secondary conditions, 26:65
- in Sézary syndrome, 27:79
- in solid tumors, 26:177
- in T-cell (cutaneous) lymphoma, 28:267
- in T-CLL of AT, 26:217
- in Waldenström's macroglobulinemia, 29:261
- inv(16) in M4, 24:257; 25:81; 26:309
- iso(11q) in Ewing sarcoma, 25:97
- isochromosomes in hematologic disorders, 25:47
- multiple myeloma, 25:309
- polycythemia vera, 25:233
- prognosis in lymphoma, 25:55
- thyroid cancer cell line, 25:27
- trisomy 1q in essential thrombocythemia, 25:185
- with inv(16), 26:309
- lp+ in lymphoma, 25:55
- lq+ and +10 in endometrial cancer, 25:21
- 1q+ or +1 in neuroectodermal tumor, 24:75
- 1q21 abnormality in secondary lymphoma, 24:7
- 3p in renal cell carcinoma, 25:179
- 5q- in preleukemia and leukemia, 26:199
- 5q- in refractory anemia, 24:159; 26:199
- 6q- in lymphoma, 25:55
- +8, +9, 13q-, 20q- in PV, 25:233
- 8q+ and i(8q) in gastric cancer, 24:63
- 9q- deletion in AML, 24:177
- +9, i(9q) or 9p+ in gastric cancer, 24:63
- 12p- in dysplastic nevus syndrome (DNS), 24:39
- 13 in neuroectodermal tumor, 24:75
- 13q14 in hematologic diseases, 24:143
- 14q+ in lymphoma, 24:271; 25:55
- 17p+ and t(5;20) in MDS, 24:371
- 20p12 in MEN-II, 24:129; 27:327
- 21 in possible secondary lymphoma, 24:7
- Chromosome instability disorders
 - dysplastic nevus syndrome, 24:299
 - in family with gastric cancer, 27:299
- Chronic granulocytic leukemia; see Chronic myelocytic leukemia
- Chronic lymphocytic leukemia (CLL)
 - chromosome changes in, 24:145; 25:109; 26:75; 28:93
 - clinical correlations, 26:75
 - cytochalasin B and EBV as mitogens, 28:93
 - oncogenes, 25:119
 - origin of +12, 28:185
 - T-cell in AT, 26:217
 - translocations, 25:109
 - +12, 25:109; 26:75; 28:93, 185
 - 13q14 in, 24:143
- Chronic myelocytic leukemia (CML)
 - APL with variant t(15;17) in, 28:349
 - atypical t(9;12;22), 25:183
 - bcr in cell lines, 25:271
 - bcr in masked Ph, 25:15
 - bcr rearrangement in masked Ph, 26:105; 27:21
 - bcr studies, 26:105; 27:21; 29:57
 - bone marrow transplantation, 26:5
 - C-bands, 25:131
 - C-bands in lymphocytes, 27:33
 - c-myc in, 27:349
 - cell colonies, 24:1
 - cell line, Ph-positive, 24:335; 25:271
 - cell surface markers, 26:25
 - chromosome changes in, 24:145, 281; 25:73, 267, 329; 26:5, 25
 - chromosome 17 and pseudo-Pelger-Huet anomaly, 25:265
 - complex Ph chromosomes, 24:281, 359

- (CML) con't
 double minutes in blastic phase, 25:253
 duplication of Ph and 9q+, 29:57
 erythrocytosis in, 24:359
 flow cytometry of cells, 24:337
 karyotype evolution, 25:73
 karyotypes, 25:75, 267
 markers in patient management, 26:25
 masked Ph, 24:281; 25:15, 165; 26:42; 27:21
 molecular studies in, 27:349
 myelofibrosis with t(1;3), 25:361
 near-haploid, 24:335
 oncogene *abl* in CML, 26:15; 27:349
 oncogene activity, 26:15
 oncogene *sis* in CML, 26:15
 PDGF in, 26:15
 Pelger-Huet anomaly, 25:265
 Ph chromosome, 24:281
 Ph-positive CML with myelofibrosis and t(1;3), 25:361
 promyelocytic crisis with t(15;17), 29:311
 pseudo-Pelger-Huet anomaly and i(17q), 25:265
 retroviral activity, 26:15
 rings in blastic phase, 25:253
 secondary and Ph+, 28:173
 t(7;11) and c-Ha-ras-1, 29:191
 t(7;11) in atypical, 26:191
 t(8;21), 25:103
 t(12;22), 25:183
 t(20;22), 25:183
 translocations other than Ph, 25:73, 267
 value of bcr analysis, 29:1
 with four Ph, 28:179
 Y polymorphism, 24:295
 3p21 and 3q25 breaks, 27:371
 -7 in secondary CML, 28:173
 +8, i(17q), +Ph, +19 in, 25:73
 13q14 in, 24:143
- Chronic myelomonocytic leukemia (CMMoL)
 t(1;7), 24:355
- Cloning
 double minutes, 24:17
 non-c-myc DNA, 24:17
- Colon
 adenocarcinoma cell line: WiDr, 27:125
 C-bands in patients, 27:111
 cancer in black family, 24:1
 carcinoid cell line, 24:17
 chromosomal changes, 29:289
 colorectal tumors, 29:289
 extracolonic manifestations of polyposis, 27:319
 inv(16) in, 27:171
 nonpolyposis cancer syndrome, 27:111
 SCE in nonpolyposis syndrome, 27:111
 sigmoid cancer with inv(16), 27:171
 t(1;13) as only change, 27:357
- Colonies
 fluoroxymidine synchronization, 24:1
 hematopoietic, 24:1
 Ph-positive cells, 24:1
 synchronization, 24:1
- Constitutional chromosome changes
 in hematologic disorders, 24:345
 r(21) in ALL, 27:219
 ring (22) with neurofibromatosis, 25:169
 risk of hematologic malignancy, 24:375
 sex chromosome abnormalities, 25:191
 t(3;6) in family with hematologic disease, 25:87
 t(6;16) and M4, 29:159
 t(13;14) carrier with testicular tumor, 25:299
- Cryptorchidism
 testicular tumors, 25:191
- Cyclophosphamide
 effects on chromosomes of lymphocytes, 29:239
- Cystic fibrosis
 c-met gene, 26:187
 molecular studies, 26:187
 P-glycoprotein gene, 26:187
- Cytogenetics; see also Karyotype, chromosome changes
 breast cancer, 24:45; 27:289
 dysplastic nevus syndrome (DNS), 24:33
 gastric cancer, 24:63
 in adrenal cancer, 26:271
 in AML, 25:329
 in ANLL, 25:329; 29:9
 in astrocytomas, 29:201
 in bladder cancer, 29:29
 in blastic phase of CML, 25:39
 in CML, 24:281; 25:75, 267, 329; 26:25, 39
 in colorectal tumors, 29:289
 in gliomas, 29:223
 in hairy cell leukemia, 24:109
 in HeLa cell line, 28:301
 in lymphoma, 24:271; 25:223; 27:335
 in MDS, 25:329; 27:39
 in megakaryoblastic leukemia, 25:259
 in meningioma, 26:127; 27:145
 in mesothelioma, 29:81
 in MPD, 24:151; 25:329
 in multiple myeloma, 25:309
 in neuroblastoma, 26:235
 in neurofibroma, 26:157
 in ovarian tumors, 26:327, 355
 in peripheral neuroepithelioma, 24:119
 in PNH, 25:259
 in prostate cancer, 26:165

- in renal cancer, 26:253
- in secondary ANLL, 29:43
- in secondary lymphoma, 24:7
- in Sézary syndrome, 27:79
- in Waldenström's macroglobulinemia, 29:261
- neuroectodermal tumor cell line, 24:75
- of ALL, 24:87
- of CLL, 25:109; 26:75; 28:93
- of gliomas, 24:163
- of hematologic malignancies, 24:143
- of lymphocyte cultures and effects of cyclophosphamide, 29:239
- of ovarian cancer cell lines, 24:231; 26:339
- of solid tumors, 26:177
- of somatic cell hybrids, 24:95
- polycythemia vera, 25:233
- prognosis in lymphoma, 25:55
- T-cell (cutaneous) lymphoma, 28:267
- thyroid cancer cell line, 25:37
- with inv(16), 26:309
- Cytometry
 - cell flow measurements, 24:191
 - genomic size of normal and neoplastic cells, 24:191
 - in CML, 24:337
- Deletion(s)
 - del(X) in dysplastic nevus syndrome (DNS), 24:39
 - in MDS, 26:227
 - in PV, 25:233
 - interstitial of 9q in AML, 24:177
 - #1 in ovarian cancer cell lines, 24:231
 - 3p- in lung cancer, 27:45
 - 3p- in renal cancer, 25:179; 26:253, 369
 - 5q- in leukemia, 26:199
 - 11p in ANLL, 28:287
 - 11q-, iron stores and MDS, 27:39
 - 13q in retinoblastoma, 27:27
 - 13q14 in MDS, 28:181
 - 21q in secondary ANLL, 29:43
- Disseminated intravascular coagulation (DIC)
 - with bone marrow necrosis, DIC and t(8;16) in AML, 24:243
- DNA
 - analysis in MEN-II, 24:129
 - c-mos localization, 24:137
 - cDNA and P-glycoprotein, 25:141
 - in glioblastoma cell line, 25:285
 - markers in multiple endocrine neoplasia, 27:327
 - measurements in adult acute leukemia, 28:213
 - measurements in normal and neoplastoid cells, 24:191
 - non-c-myc in carcinoid, 24:17
 - p446 probe, 24:17
 - polymorphic probes, 28:335
 - rDNA in mouse leukemia line, 29:109
 - reiterated sequences in cancer, 28:163
 - studies in CML cell lines, 25:271
- Double minute chromosomes
 - blastic phase of CML, 25:253
 - CML in blastic phase, 25:253
 - in a gastric cancer, 24:64
 - in AMMoL, 25:1
 - in astrocytomas, 29:201
 - in Bloom syndrome fibroblasts, 26:287
 - in breast cancer, 24:52
 - in c-myc amplification, 28:127
 - in colon carcinoid cell line, 24:17
 - in mouse mammary cancer line, 25:317
 - in ovarian cancer cell line, 24:231
 - in refractory anemia, 28:367
 - in Shionogi cell line, 25:317
 - non-c-myc DNA, 24:17
- Down syndrome
 - acute leukemia in, 24:345; 28:55, 155
 - ALL, 28:155
 - ANLL, 28:155
 - chromosome changes in leukemia, 28:155
 - epidemiology, genetics, cytogenetics and leukemogenesis, 28:55
 - hematologic disorders, 24:345; 28:155
 - transient megakaryoblastic proliferation, 28:373
- Dysgerminoma
 - chromosome changes in, 26:327
 - i(12p) in, 26:327, 355
 - in gonadal dysgenesis, 25:191
- Dysplastic nevus syndrome (DNS) and malignant melanoma, 24:299
 - chromosome changes in, 24:33, 299
 - cytogenetics, 24:299
 - hyperdiploidy in, 24:33
 - lymphocytes, 24:33
 - SCE in cells, 24:33
- Endometrial cancer
 - karyotype in well-differentiated adenocarcinoma, 25:21
- Eosinophils
 - in M4 with inv(16), 29:327
 - inv(16) in, 29:327
 - MPD with chromosome 7 abnormality, 26:209
- Erythroleukemia, acute
 - Auer rods and cytogenetics, 28:191
 - c-Ha-ras expression in cell lines, 28:301
 - cell line (D5A1), 28:301
 - DNA measurements in adult, 28:201

- Esthesioneuroblastoma
t(11;22), 29:155
- Ewing sarcoma
isochromosome 11, 25:97
- Familial
bladder cancer, 27:161
cancer, 24:11
colon cancer, 24:11
dysplastic nevus syndrome (DNS), 24:33
hematologic malignancies and
 constitutional t(3;6), 25:87
in black family, 24:11
polyposis coli, 27:319; 28:245
polyposis coli and neurofibromatosis,
 28:245
t(6;16) and M4, 29:159
XY gonadal dysgenesis and tumors,
 25:191
- Fanconi anemia
cancer proneness, 25:85
chromosome analysis, 25:37; 26:85
chromosome breakage, 25:37; 26:85
cytogenetic toxicity of paraquat and
 streptonigrin, 25:37
- Fibroblasts
chromosome changes in, 24:33
dysplastic nevus syndrome (DNS), 24:33
hyperdiploidy and cancer, 26:261
in nasopharyngeal cancer, 26:261
SCE in, 24:33
- Fluorodeoxyuridine
hematopoietic colonies, 24:1
synchronization, 24:1
- Fragile sites
fra(16)(q22) in ANLL, 25:81
heritable and cancer, 25:81, 26:95
in nonpolyposis colon cancer syndrome,
 27:111
lymphocytes, 26:95
malignancy and, 26:95
noninvolvement of 10q24.2 in rectal
 cancer, 25:7
- Gastric cancer
chromosome instability in family with,
 27:299
cytogenetic findings in, 24:63
 #7 in, 24:63
 8q+ and i(8q), 24:63
 #9 in, 24:63
 +9, i(9q) or 9p+ in, 24:63
- Gene(s)
amplification in gliomas, 29:165
amplification in tissue culture, 29:119
amplified in HSR, 26:245
cystic fibrosis, 26:187
locus for P-glycoprotein, 25:141
mdrl-gene, 26:187
N-myc in neuroblastoma, 26:235
P-glycoprotein, 26:187
probes, 27:91
- Glioblastoma
cell line, 25:285
oncogene expression in cell line, 25:285
- Glioma; see also Brain tumors
astrocytoma, 29:201
cell lines, 24:163; 25:285
chromosome changes, 24:163; 25:285;
 29:165, 223
gene amplification, 29:165
+7 in, 29:323
- Gonadal dysgenesis
Brunner tumor, 25:191
dysgerminoma, 25:191
gonadoblastoma, 25:191
hilus-cell adenoma, 25:191
neoplasia in, 25:191
review, 25:191
tumors in, 25:191
- Gonadoblastoma
in gonadal dysgenesis, 25:191
Turner syndrome, 25:191
- Hairy cell leukemia (HCL)
cytogenetic studies in, 24:109
 #3, #10 and #17 in, 24:109
- Hematopoietic (Hematologic) disorders
13q14 in malignancies, 24:143
colonies, 24:1
constitutional chromosome changes,
 24:345
isochromosomes, 25:47
myeloproliferative diseases, 24:151
secondary disorders due to therapy,
 26:65
- Hepatoma
cell line, 26:279
karyotype of cell line, 26:279
- Hereditary
ovarian cancer, 25:247
- Hermaphroditism
neoplasia in, 25:191
- Heterochromatin
C-bands in cancer families, 27:261
C-bands in CML, 27:33
C-bands in ovarian and breast cancer,
 28:77
constitutive of Y in CML, 24:295
in hydatidiform moles, 26:143
in multiple myeloma, 28:101
of Y in boys with various tumors,
 25:351
- Heteromorphism; see also
 Heterochromatin
C-bands in cancer families, 27:261

- C-bands in CML, 27:33
- C-bands in multiple myeloma, 28:101
- C-bands in nervous system tumors, 27:185
- C-bands in nonpolyposis colon cancer syndrome, 27:111
- C-bands in ovarian and breast cancer, 28:77
- Heterozygosity
 - chromosome 13 in polyposis, 28:325
 - loss in osteosarcoma, 28:335
 - loss in polyposis tumor (duodenal), 28:335
- Hilus-cell adenoma
 - in gonadal dysgenesis, 25:191
- Histiocytoma
 - chromosome findings, 29:97
 - malignant (fibrous), 29:97
 - +7 in, 29:97
- Homogeneously staining regions (HSR)
 - amplification, 29:139
 - in breast cancer, 24:52
 - in cell line, 24:17
 - in colon carcinoid, 24:17
 - SCE in, 26:245
 - unequal crossing-over and, 29:139
- Hybrids
 - cell lines (LM, A9, Rag), 24:95
 - mouse cells, 24:95
 - somatic cell, 24:95
- Hydatidiform mole
 - chromosome heteromorphism, 26:143
 - complete, 29:271
 - cytogenetics of trophoblasts, 29:271
 - DNA-aneuploidy, 27:225
 - genetic markers, 26:143
 - heterozygous 46,XX, 26:143
 - heterozygous 46,XY, 26:143
 - homozygous 46,XX, 26:143
- Hyperdiploidy
 - in dysplastic nevus syndrome (DNS), 24:33
 - in fibroblasts of cancer patients, 26:261
 - in nasopharyngeal cancer, 26:261
- Immunoglobulin(s)
 - atypical lymphoid hyperplasia, 27:251
- Insertions
 - ins(2;13) in CLL, 24:143
 - ins(4;11) in PV, 24:238
 - ins(6;11) in T-cell lymphoma, 27:367
 - ins(7;13) in CLL, 24:143
 - ins(11;21) in MDS, 27:42
- In situ hybridization
 - at 20p12 in MEN-II, 24:129
 - c-Ha-ras-1 in M2 and CML, 29:191
 - c-met, 26:187
 - c-mos localization, 24:137
 - c-sis in neurofibromatosis, 25:169
 - P-glycoprotein, 26:187
 - ring (22) in neurofibromatosis, 25:169
- Inversion
 - inv(5) in MDS, 29:171
 - inv(7), inv(14) and fragile sites, 25:95
 - inv(12) constitutional, 24:345
 - inv(12) in malignancies, 28:113
 - inv(12)(p11q14) in DNS, 24:38, 39
 - inv(16) in a biphenotypic leukemia lacking monocytic markers, 25:367
 - inv(16) in AMoL (M5b), 26:309
 - inv(16) in colon cancer, 27:171
 - inv(16) in eosinophils of M4, 29:327
 - inv(16) in M4 in XY/XY, 29:331
 - inv(16) in t-ANLL, 27:167
 - inv(16)(p13q22), fra(16)(q22) in ANLL, 25:81
 - #16 in AMMoL (M4), 24:257; 25:367; 26:309; 29:327
- Isochromosomes
 - hematologic diseases, 25:47
 - i(p) in duplicate in MDP, 29:319
 - i(7q), i(11q), i(17q) and i(21q), 25:47
 - i(12p) in dysgerminoma, 26:355
 - i(12P) in ovarian tumors, 26:355
 - i(17q) in lymphoma, 25:55
 - 9p in PNH, 25:259
 - 11q in Ewing's sarcoma, 25:97
- Karyotype(s)
 - adrenal cancer, 26:271
 - evolution in brain tumors (gliomas), 24:163
 - evolution in lymphoma, 24:271
 - evolution in M4 with inv(16), 24:257
 - evolution in PV, 25:243
 - in AML, 25:329
 - in ANLL, 25:329; 29:9
 - in astrocytomas, 29:201
 - in bladder cancer, 29:29
 - in blastic crisis of CML, 26:39
 - in breast cancer, 24:45; 27:289
 - in CLL, 25:109; 26:75; 28:93
 - in CML, 24:281; 25:75, 267, 329
 - in colorectal tumors, 29:289
 - in gastric cancer, 24:63
 - in gliomas, 24:163; 29:223
 - in HeLa cell line, 28:301
 - in hematologic malignancies, 24:143; 25:329
 - in lymphoma, 24:271; 25:223, 27:335; 28:267
 - in MDS, 25:329; 27:39
 - in myeloproliferative diseases, 24:143, 151; 25:329
 - in neuroectodermal tumor cell line, 24:75

- Karyotype(s) con't
 in peripheral neuroepithelioma, 24:119
 in polycythemia vera, 25:233
 in secondary lymphoma, 24:7
 in Sézary syndrome, 27:79
 in somatic cell hybrids (mouse), 24:95
 meningioma, 26:127; 27:145
 neurofibroma, 26:157
 ovarian tumors, 26:327, 339, 355
 prostate cancer, 26:165
 renal cancer, 26:253
 T-cell lymphoma, 28:267
- Kidney; see also Renal cell carcinoma
 telomeric association, 28:363
 tumors, embryonal origin, 24:189
 3p in renal cell carcinoma, 25:179;
 26:253, 363
 3p- as only change, 26:363
 3p12-14 in, 26:253, 363
- Klinefelter syndrome
 acute leukemia, 26:375
 hematologic disorders, 24:345
 neoplasia in, 25:191
- Large bowel
 cancer, 24:11
 cancer in black family, 24:11
 carcinoid cell line, 24:17
 mucinous adenocarcinoma, 24:11
 noninvolvement of fragile site 10q24.2
 in rectal cancer, 25:1
- Lipogenic tumors; see also Adipose tissue
 tumors
 cytogenetics, 24:319; 28:137
 liposarcoma, 28:137
 rings in, 24:319
- Liposarcoma
 chromosome changes, 28:137
 myxoid with t(12;16), 26:185
 t(12;16), 26:185; 28:137
- Lung
 adenocarcinoma cell lines, 26:317
 adenocarcinomas (metastatic), with
 3p-, 25:355
 cancer, oncogene studies, 27:45
 loss of heterozygosity at 3p21 in cancer,
 27:361
 small cell cancer, 27:45
 3p- in lung cancers, 25:355; 27:45, 361
- Lymph nodes
 in lymphoma, 25:219
 -Y in, 25:219
- Lymphocytes
 chromosome changes in, 24:33; 25:303
 cyclophosphamide effects, 29:239
 dysplastic nevus syndrome (DNS),
 24:33, 299
 fragile sites, 26:95
 malignant melanoma patients, 24:299
 proportions of B and T in culture,
 29:151
 SCE in 24:33
 thyroid cancer patients, 25:303
- Lymphoid hyperplasia
 atypical, 27:251
 cytogenetics in atypical, 27:251
 molecular studies in, 27:251
 t(2;19) in, 27:251
- Lymphoma
 Abelson virus induced in mouse cells,
 28:119
 Burkitt type translocation, 24:225
 cell kinetics, 28:357
 chromosome changes in secondary, 24:7
 cutaneous T-cell, 28:267
 cytogenetic findings, 25:55; 27:335
 diffuse large cell with t(2;8), 24:225
 in transplant recipient, 24:7
 indolent, 27:335
 isochromosomes, i(7q), i(11q), i(17q) and
 i(21q), 24:47
 karyotypic evolution in, 24:271
 Kiel classification, 25:56
 molecular studies in, 27:191
 prognostic implication of chromosomes
 changes, 25:55
 secondary?, 24:7
 Sézary syndrome, 27:79
 T-cell, 28:267
 t(14;18) in, 25:55, 219
 -Y in, 25:219
 +3, +7, +12, 1p+, 14q+, 6q-, i(17q)
 in lymphoma, 25:55
 +12 in AIDS, 29:245
- Malignant histiocytosis
 7q-, 28:353
- Malignant melanoma; see Melanoma
- Markers
 alph-L-fucosidase in hereditary ovarian
 cancer, 25:247
 cell surface in CML, 26:25
 esterase D in retinoblastoma, 27:27
 hydatidiform moles, 26:143
 lipid associated sialic acid, 25:247
- Megakaryoblastic leukemia
 chromosome changes, 25:259
 evolution from PNH, 25:259
 possible (transient) in Down's
 syndrome, 28:373
- Melanoma
 chromosome changes in Syrian hamster,
 25:123
 cytogenetics, 24:299

- dysplastic nevus syndrome, 24:33, 299
- mouse, 22:81
- transplantable, 25:123
- Mendelian
 - mutations and cancer, 26:85
- Meningioma
 - clinical significance of chromosome changes, 26:127
 - cytogenetic studies, 26:127; 27:145
 - recessive genes, 27:145
- Mesothelioma
 - cytogenetic findings, 29:75
- Methods
 - analysis of bladder tumor biopsies, 29:103
 - BrdU and cell synchronization, 28:229
 - chromosomes in bladder cancer, 29:23, 103
 - cytogenetic analysis of colonies, 24:1
 - fluorodeoxyuridine synchronization, 24:1
 - G-banding, 28:229
 - hematopoietic colonies, 24:1
 - immunoenzymatic staining, 27:229
 - marrow analysis, 28:229
 - ovarian tumors, 27:9
 - simultaneous demonstration of chromosomes and cell surface markers, 27:229
 - solid tumors, 27:9
- Mitogens
 - cytochalasin B and EBV, 28:93
 - for B-cells, 24:109; 28:93
- Mitotic
 - recombination and tumors, 27:5
- Mole(s); see Hydatidiform mole
- Molecular studies
 - amplification of N-myc, 26:235
 - bcr in CML, 29:1
 - bcr in CML cell lines, 25:271
 - bcr in masked Ph in CML, 25:15; 26:105; 27:21
 - c-Ha-ras-1 in M2 and CML, 29:191
 - carcinoid cell line, 24:17
 - in atypical lymphoid hyperplasia, 27:251
 - in Bloom's syndrome cell lines, 26:287
 - in cancer, 28:163
 - in CML, 26:15, 105; 27:349
 - in CML cell lines (EM-2 and EM-3), 25:271
 - in erythroleukemia cell line, 28:301
 - in lung cancer, 27:45, 361
 - in lymphoma, 27:191
 - in MEN-II, 24:129
 - in mouse leukemia cells, 29:109
 - in neuroblastoma, 26:235
 - in osteogenic sarcoma, 29:303
 - in peripheral neuropithelioma, 24:119
 - in PLL, 27:89
 - N-myc in neuroblastoma, 26:235
 - of fms in ALL cell line, 25:341
 - of heterozygosity, 28:335
 - oncogene activity in CML, 26:15
 - P-glycoprotein locus on 7q36; 25:141
 - recombination and malignancy, 26:95
 - reiterated DNA sequences, 28:163
 - restriction endonucleases and marker chromosomes, 24:367
 - retroviral activity in CML, 26:15
 - with c-mos in t(8;21), 24:137
 - +12 in CLL, 28:185
- Mouse
 - cell lines, 24:95; 25:317
 - chromosome changes in mammary cancer cell line, 25:317
 - cytogenetics of cell lines, 24:95; 25:317
 - cytogenetics of leukemia cells, 29:109
 - double minutes in cell lines, 25:317
 - melanoma (B16-F10), 29:81
 - rDNA in mouse leukemia cells, 29:109
 - somatic cell hybrids, 24:95
- Müllerian tumor
 - ovary, 26:355
- Multiple endocrine neoplasia syndrome (MEN-II)
 - changes in blood lymphocytes, 25:303; 28:253
 - chromosome analysis in, 24:129; 28:253
 - chromosome 20, 27:327; 28:253
 - del (20) p12.2, 24:129; 28:253
 - DNA analysis in, 24:129
 - DNA markers on chromosome 20, 27:327
 - linkage analysis, 27:327
 - Type II, 24:129; 26:85; 28:253
 - 13q RFLP, 29:183
- Multiple myeloma; see Myeloma
- Myelodysplastic syndromes (MDS)
 - cell kinetics, 28:357
 - chromosome changes, 24:145; 25:329; 26:199, 227; 27:39
 - clinical, morphologic and cytogenetic correlations, 26:227
 - constitutional chromosome changes, 24:345
 - cytogenetics in siblings with MDS, 27:241
 - deletions in, 26:227; 27:39
 - + der(21) in RA with excess blasts, 25:175
 - drug induced, 26:213
 - high platelet count and t(3;8), 27:1
 - idic(X) in, 27:215

- (MDS) con't
 inv(5q) in secondary MDS, 29:171
 inv(12), 28:113
 iron stores in, 27:39
 normal karyotypes, 25:161
 Ph-positive, 26:213
 pleributazone-induced, 26:213
 RA with excess of blasts, 25:175; 26:199
 RAEB and t(6;9), 29:135
 refractory anemia, 24:159; 26:199
 refractory anemia with -2 and DM, 28:367
 rheumatoid arthritis, 25:161
 secondary, 26:65
 siblings with, 27:241
 t(1;3), 28:277
 t(1;7), a correction, 25:187
 t(1;7) in CMMoL, 24:355
 t(3;8) with high platelet count, 27:1
 t(5;20) and 17p+ in, 24:371
 t(6;9), 29:135
 t(7;11) in, 26:191
 t(8;21) in RA with excess blasts, 25:175
 5q-, 26:199
 5q- in refractory anemia, 24:159; 26:199
 + 9 in, 27:73
 11q- and iron stores, 27:39
 13q14 in, 24:143
 13q14 loss, 28:181
 + 14 in RAEB, 29:315
- Myelofibrosis; see also Myeloproliferative diseases (MPD)
 in Ph-positive CML, 25:361
 t(1;3) in, 25:361
- Myeloid metaplasia; see Myeloproliferative disorders
- Myeloma, multiple
 C-bands, 28:101
 chromosome findings, 25:309, 375
 t(14;18) in, 25:375
 1q-, 2p+, 2q+, 7q-, 7p- in, 25:309
- Myeloproliferative disorders (MPD)
 blastic transformation of MMM, 24:221
 chromosome changes, 24:145, 151
 chromosome 7, 26:209
 constitutional chromosome changes, 24:345; 25:87
 constitutional t(3;6) in myelofibrosis, 25:87
 cytogenetic studies, 24:151
 eosinophilic, 26:209
 i(17q) in myelofibrosis with myeloid metaplasia, 24:221
 in myeloid metaplasia, 24:151
 inv(12), 28:113
 iso(9p) in duplicate, 29:319
 MMM-published cases with blastic phase, 24:223
 myelofibrosis, 24:151
 secondary MMM, 26:65
 t(1;7), a correction, 25:187
 + 9 in, 27:73
 13q14 in, 24:143
- Nasopharyngeal cancer
 genetic predisposition, 26:261
 in vitro hyperdiploidy, 26:261
- Near-haploid (y)
 conversion in CML, 24:335
- Neoplasia
 cryptorchidism, 25:191
 gonadal dysgenesis, 25:191
 pseudohermaphroditism, 25:191
- Neurinoma(s)
 cytogenetic analysis, 28:187
- Neuroblastoma
 chromosome changes and prognosis, 29:175
 cytogenetics of, 26:235
 disseminated, 26:235
 N-myc in, 26:235
 oncogene (N-myc) amplifications, 26:235
 prognosis and cytogenetics, 29:175
- Neuroectodermal tumors
 cell line, 24:75
 chromosomal changes, 24:75
 peripheral neuroepithelioma, 24:119
 primitive, 24:75
 1q+ or +1 in, 24:75
 -13 in, 24:75
- Neuroepithelioma
 c-sis translocation, 24:119
 peripheral, 24:119
- Neurofibromatosis
 and polyposis coli, 28:245
 c-sis studies, 25:169
 cytogenetic clones, 26:157
 in situ hybridization, 25:169
 recurrent, 26:157
 ring(22), 25:169
- Non-Hodgkin lymphoma; see Lymphoma
- Nucleolar organizer regions (NOR)
 cistrons (rDNA) in mouse leukemia lines, 29:109
 in bone marrow cells, 25:65
 in CML, 25:131
 Philadelphia chromosome, 25:131
 rRNA amplification, 29:119
- Nude mouse passage
 ovarian cancer cells, 28:201
- Oncogene(s)
 abl and sis in CML, 26:15
 abl, erb B, myc and Ha-ras in glioblastoma cell line, 25:285
 activity in CML, 26:15
 c-abl and c-myc in CML, 27:349

- C-Ha-ras expression in leukemia cell line, 28:301
c-Ha-ras-1 in M2 and CML, 29:191
c-met, 26:187
c-mos in t(8;21), 24:137
c-mos locus, 24:137
c-myc amplification in human leukemia cell line (HL-60), 28:127
c-myc overexpression in PLL, 27:89
c-sis in neurofibromatosis, 25:169
c-sis in peripheral neuroepithelioma, 24:119
cytosine-arabioside effect on c-myc, 27:89
expression in Bloom's syndrome cell lines, 26:287
expression in glioblastoma cell line, 25:285
fms in ALL with 5q-, 25:341
in lung cancer (Ha-ras, Ki-ras, N-ras, myb, and myc), 27:45
in lymphoma, 27:191
localization of C-Ha-ras-1 in M2 and CML, 29:191
N-myc amplification in neuroblastoma, 26:235
retroviral activity in CML, 26:15
translocation of c-sis, 24:119
- Osteosarcoma
cell line, 24:327
esterase D expression, 24:327
in patient with retinoblastoma, 28:335
platelet derived growth factor, 29:303
#13 in, 24:327; 28:335
- Ovarian
alpha-L-fucosidase variant, 25:247
carcinoma cell lines, 24:231; 26:339, 28:201
cytogenetic findings, 24:231; 26:327, 339, 355; 28:201
dysgerminoma, 26:327, 355
hereditary cancer, 25:247
lipid associated sialic acid, 25:247
Müllerian tumor, 26:355
nude mouse passage, 28:201
tumors, 26:327, 355
tumors in sex chromosome disorders, 25:191
1, 3 and 6 in, 26:339, 355
1, 3, 6, 6, 11, and 14, 26:355
- Pancreas
cytogenetics of anaplastic carcinoma, 29:253
- Paroxysmal nocturnal hemoglobinuria (PNH)
chromosome changes, 25:259
evolving into megakaryoblastic leukemia, 25:259
subclonal evolution, 25:259
t(7;11) in, 26:191
- Ph chromosome; see Philadelphia chromosome and translocation
- Philadelphia (Ph) chromosome and translocation
atypical t(9;12;22), 25:183
bcr in masked Ph, 25:15; 26:105; 27:21
bcr studies, 25:271; 26:105; 27:349; 29:1, 57
complex in, 27:375
complex translocations, 24:281; 25:75
DNA studies, 25:271
duplication, 29:57
four Ph chromosomes in CML, 28:179
in CML, 24:281; 25:75, 165, 267; 27:375
in drug induced MDS, 26:213
in near-haploid line, 24:335
in thrombocythemia, 25:227
lymphoid blast crisis in thrombocythemia, 25:227
masked Ph, 24:281; 25:15, 165; 26:42; 27:21
masked Ph in blast crisis, 26:42
NOR, 25:131
t(5;22;9), 24:281; 25:15
t(8;9;22), 24:281
t(9;9;22;11), 24:281
variant, 25:267; 26:105; 27:375
- Plasma cell
cytogenetics of cell lines, 27:135
lines, 27:135
- Platelet-derived growth factor
composition, 29:303
gene localization, 29:303
in osteogenic sarcoma, 29:303
- Pleomorphic adenoma
cytogenetics, 28:237
polyclonal chromosome evolution, 28:237
with marker similar to one in endometrial cancer, 27:177
with t(3;8;8), 27:177
- Polycythemia vera (PV)
chromosomes in, 25:233
chromosomes 5 and 7, 25:233
inv(12), 28:113
secondary ANLL or MDS, 26:65
+8, +9, 13q-, 20q-, 25:233
- Polymorphism(s)
C-bands in ovarian and breast cancer, 28:77
of C-bands in CML, 27:33
of Y in boys with various tumors, 24:351
of Y in CML, 24:295
- Polyposis coli
and neurofibromatosis, 28:245

- Polyposis coli con't
 - extracolonic manifestations, 27:319
 - familial, 27:319; 28:245
- Pre-B ALL
 - t(1;19) in, 25:379
- Preleukemia
 - 5q- in, 26:199
- Premature chromosome condensation (PCC); see also Prophasing
 - and prophasing, 27:181
 - in acute leukemia, 27:51, 63
 - in breast cancer, 24:52
 - in cervical carcinoma, 24:263
 - methodology, 27:51, 63
 - relapse prediction, 27:51, 63
- Probes
 - bcr in CML cell lines, 25:271
 - c-mos, 24:137
 - in lymphomas, 27:191
 - molecular, 27:191
 - p446, 24:24
- Prognostic implications
 - cytogenetic findings in lymphoma, 25:55
 - cytogenetics in CLL, 25:119
- Prolymphocytic leukemia (PLL)
 - acquired Robertsonian translocation, 25:293
 - c-myc overexpression, 27:89
 - cytosine-arabioside therapy effect, 27:89
- Prophasing
 - definition, 27:181
 - in acute leukemia, 27:51, 63
 - in breast cancer, 24:52
 - in cervical cancer, 24:263
 - methodology, 27:51, 63
 - relapse predictor, 27:51, 63
- Prostate
 - cancer, 26:165
 - cell line (xenografted), 26:165
 - karyotypic analysis, 26:165
 - small cell carcinoma, 26:165
 - tumors, embryonal origin, 24:189
- Protooncogene; see Oncogenes
- Pseudohermaphroditism
 - female, 25:191
 - genetic forms, 25:191
 - male, 25:191
 - testicular tumors, 25:191
- Pseudo-Pelger-Huet anomaly
 - chromosome 17, 25:265
 - i(17q), 25:265
 - in CML, 25:265
- Rectal cancer; see also Large bowel and colon cancer
 - breakpoints in cancer, 25:7
 - chromosome changes, 29:289
 - noninvolvement of fragile site 10q24.2, 25:7
- Refractory anemia
 - chromosomes changes in, 25:329; 26:199
 - late appearing marker, 24:159
 - t(2;11) in, 25:335
 - t(8;21) and +der(21) in RA, 25:175
 - with excess of blasts in transformation, 25:175; 26:199
 - 5q-, 24:159; 26:199
 - +8, 24:159
 - +14 in RAEB, 29:315
- Refractory anemia with excess of blasts (RAEB); see Refractory anemia and myelodysplastic syndromes
- Renal cell carcinoma; see also Kidney
 - genetic mechanism for 3p change, 25:179
 - in von Hippel-Lindau, 27:345
 - recurrent 3p rearrangement, 25:179; 26:253, 369
 - telomeric association, 28:363
 - 3p- as only change, 26:369
 - 3p12-14 in, 26:253, 369
- Restriction endonucleases
 - identification of marker chromosomes by, 24:367
- Retinoblastoma
 - chromosome breakpoint, 27:27
 - del(13q), 27:27
 - esterase D, 27:27
- Retrovirus
 - activity in CML, 26:15
- Reviews
 - abnormal sex differentiation and neoplasia, 25:191
- Rhabdomyosarcoma
 - alveolar, 25:373
 - chromosome changes in, 28:157
 - in Down's syndrome, 28:155
 - t(2;13) in, 25:371, 373
- Rheumatoid arthritis
 - leukemia and MDS in, 25:161
 - normal karyotypes in acute leukemia and MDS, 25:161
- Ring(s)
 - blastic phase of CML, 25:253
 - constitutional r(22) in neurofibromatosis, 25:169
 - in a gastric cancer, 24:64
 - in breast cancer, 24:52
 - in CML in blastic phase, 25: 253
 - in lipogenic tumors, 24:319
- Robertsonian translocation
 - acquired in leukemia, 25:293
 - prolymphocytic leukemia, 25:293
 - review (in cancer), 25:293
 - Table, 25:298

- Salivary gland tumors
 benign, 28:237
 cytogenetic findings, 24:205; 28:237
 mixed, 24:205; 28:237
 polyclonal evolution, 28:237
 #8 in, 24:205; 28:237
- Sarcoma
 Ewing with iso(11q), 25:97
 liposarcoma, 26:185; 28:137
 myxoid liposarcoma, 26:185
 osteosarcoma, 24:327
 rhabdomyosarcoma with t(2;13), 25:371, 373
 synovial, 26:179, 181
- Second International Workshop on
 Chromosomes in Solid Tumors
 abstracts, 28:27-47
 editorial, 28:1
 historical, 28:5
 preface, 28:3
 summary, 28:49
- Secondary hematologic disorders
 chromosome changes in 26:65
 MDS following phenylbutazone, 26:213
 Ph-chromosome in, 26:213
 Ph-positive CML, 28:173
 therapy and, 26:65, 213
- Sexual differentiation
 abnormal, 25:191
 neoplasia, 25:191
- Sézary syndrome
 cytogenetic studies in, 27:79
- Shionogi carcinoma 115; see Mouse and cell lines
- Silver banding; see Nucleolar organizer regions (NOR)
- Sister chromatid exchange (SCE)
 cells of dysplastic nevus syndrome, 24:33
 effects of tobacco, 27:15
 in fibroblasts of DNS, 24:33
 in HL-60 cells, 27:311
 in HSR, 26:245
 in lymphocytes of DNS, 24:33
 in melanoma patients, 24:308
 in nonpolyposis colon cancer syndrome, 27:111
- Solid tumors; see also Tumors
 cytogenetics, 26:177; 28:1-47
 Second International Workshop, 28:1-47
- Sperm
 "hot spot" in #1 of patient treated for Wilms tumor, 29:91
- Stomach cancer
 cytogenetics in, 24:63
 #7 in, 24:63
 8q+ and i(8q), 24:63
 +9, i(9q) or 9p+ in, 24:63
 #9 in, 24:63
- Supernumerary nipples
 urologic malignancies, 24:185
- Sweet syndrome
 acute leukemia with t(3;5), 28:87
- Synchronization
 fluorodeoxyuridine, 24:1
 hematopoietic colonies, 24:1
- Synovial sarcoma
 chromosome change, 26:179, 181
 t(X;18), 26:179, 181; 29:179
- T-cell(s)
 CLL in AT, 26:217
 cutaneous lymphoma, 28:267
 in PHA-stimulated lymphocyte cultures, 29:151
 ins (6;11) in lymphomas, 27:367
 leukemic cell receptors, 28:327
 molecular studies, 27:251
 receptors, 28:327
 Sézary syndrome, 27:79
- Techniques; see Methods
- Telomeric association
 in ALL, 24:87
 renal tumors, 28:363
- Testicular
 t(13;14) carrier and tumor, 26:297
 tumor, 26:297, 303
 tumor (secondary lymphoma), 24:7
 tumors, embryonal origin, 24:189; 25:191
 tumors in sex chromosome anomalies, 25:191
- Testicular feminization
 neoplasia in, 25:191
- Tetraploidy
 in ALL, 29:129
- Tetrasomy
 +8, +8 in ANLL, 27:269
- Thrombocythemia
 constitutional chromosome changes, 24:345
 evolving into lymphoid blast crisis, 25:227
 in CML with chromosome 3 changes, 27:371
 long survival, 25:185
 Ph-positive, 25:227
 trisomy 1q, 25:185
- Thrombocytosis
 +9, 27:73
- Thyroid cancer
 cell line, 25:27
 cytogenetic studies in cell line, 25:27, 303
 lymphocytes of patients with, 25:303
 medullary, 25:27, 303

Tobacco

SCE, 27:15

Transitional cell carcinoma

ureter with +7 and i(5p), 25:369

+7 and i(5p) in, 25:369

Translocations

in ALL, 26:59

in ANLL, 26:51; 29:9

in breast cancer, 27:289

in lung adenocarcinoma cell lines,
26:317

in lymphoma, 27:335; 28:267

in meningioma, 26:127

in mouse melanoma lines, 29:81

in neurofibroma, 26:157

in salivary gland tumors, 24:205; 28:237

in secondary (treatment related) ANLL,
29:43

in somatic cell hybrids (mouse), 24:95

in synovial sarcoma, 26:179, 181

other than Ph in CML, 25:73

Robertsonian in cancer and leukemia,
25:298, 335

t(1;1) in ALL, 24:91

t(1;2) in ALL, 24:90

t(1;2) in multiple myeloma, 25:309

t(1;3) in MDS, 28:277

t(1;3) in Ph-positive CML with
myelofibrosis, 25:361

t(1;4) in blastic phase CML, 25:28

t(1;6) in breast cancer, 27:291

t(1;6;13;22) in CML, 25:75

t(1;7) in CMMoL, 24:355

t(1;7) in MPD, 24:154

t(1;7) in myeloma, 25:375

t(1;7), a correction (MDS, ANLL, MPD),
25:187

t(1;7;14) in meningioma, 27:145

t(1;9) in MPD, 24:154

t(1;9) in PV, 25:240

t(1;9;22) Ph in CML, 27:375

t(1;11) in AMMoL, 24:181

t(1;11) in breast cancer, 27:293

t(1;11) in dysplastic nevus syndrome
(DNS), 24:39

t(1;12) constitutional in ANLL, 24:345

t(1;13) in ALL, 24:90

t(1;13) in AML (M2), 24:243

t(1;13) in colon cancer, 27:357

t(1;13) in lymphoma, 25:223

t(1;13;14) in CLL, 25:109

t(1;16) in ALL, 24:90

t(1;17) in blastic phase CML, 25:28

t(1;17) in CLL, 25:109

t(1;17) in MDS, 27:243

t(1;19) in pre-B ALL, 25:379

t(1;21) constitutional in MPD, 24:345

t(1;22) in neurofibroma, 26:157

t(2;2) in CML, 25:75

t(2;7) in myeloma, 25:375

t(2;7;14) in meningioma, 27:145

t(2;8) in diffuse large cell lymphoma,
24:225

t(2;10) in CLL, 25:109

t(2;10) in renal cancer, 26:253

t(2;11) in CML, 25:335

t(2;11) in MDS, 27:42

t(2;13) in rhabdomyosarcoma, 25:371,
373

t(2;14) in CML, 25:75

t(2;14) in dysplastic nevus syndrome
(DNS), 24:39

t(2;15) in AML (M2), 24:243

t(2;15) in dysplastic nevus syndrome
(DNS), 24:39

t(2;15;17) in APL, 28:113

t(2;19) in atypical lymphoid
hyperplasia, 27:251

t(2;19) in lymphoma, 25:223

t(2;21) in CLL, 24:145

t(2;21) in multiple myeloma, 25:309

t(3;3) in CML, 25:75

t(3;5) in ANLL, 28:261

t(3;5) in CML, 25:75, 267

t(3;5) in M2 in Sweet's syndrome, 28:87

t(3;6) constitutional in ANLL, 24:345

t(3;6) constitutional in family with
hematologic malignancies, 25:87

t(3;8) in CML, 25:75

t(3;8) in dysplastic nevus syndrome
(DNS) 24:39t(3;8) in MDS with high platelet count,
27:1

t(3;8) in salivary gland tumors, 24:205

t(3;8;8) in pleomorphic adenoma, 27:177

t(3;12) in adrenal cancer, 26:217

t(3;17) in CML, 25:75

t(3;17) in dysplastic nevus syndrome
(DNS), 24:39

t(3;17) in MDS and ANLL, 26:199

t(3;19) in CLL, 25:109

t(3;20) in CML, 27:371

t(3;21) in MPD, 24:154

t(4;9;22) Ph in CML, 27:375

t(4;11) in adrenal cancer, 28:343

t(4;13;17) in CLL, 24:145

t(4;14) constitutional in ALL, 24:345

t(4;14) in meningioma, 26:127

t(4;17) in acute leukemia, 28:327

t(4;17) in dysplastic nevus syndrome
(DNS), 24:38

t(4;18) in CLL, 25:109

t(4;22) masked Ph in CML, 25:165

t(5;7) in dysplastic nevus syndrome
(DNS), 24:38

t(5;8) in ovarian tumor, 26:327

- t(5;15) in lung cancer, 25:355
t(5;18) in adrenal cancer, 26:271
t(5;20) in MDS, 24:371
t(5;22;9) in Ph translocation, 24:281;
25:15
t(6;7) in dysplastic nevus syndrome,
24:39
t(6;7) in neuroectodermal tumor cell
line, 24:84
t(6;9) in ANLL, 29:363
t(6;9) in MDS, 26:135
t(6;11) in M4, 26:351
t(6;19;22) in T-cell CLL in AT, 26:217
t(6;22) in PV, 25:241
t(7;8) in salivary gland tumors, 24:205
t(7;8;9) in salivary gland tumors, 24:205
t(7;11) c-Ha-ras-1 in M2 and CML,
29:191
t(7;11) in nonlymphocytic neoplasia,
26:191
t(7;14) and fragile sites, 26:95
t(7;14) in dysplastic nevus syndrome
(DNS), 24:38
t(7;19) in dysplastic nevus syndrome
(DNS), 24:39
t(7;19) in PV, 25:237
t(7;22) in CML, 25:267
t(8;9) in salivary gland tumors, 24:205
t(8;9;22) in Ph translocation, 24:281
t(8;9;22) variant Ph, 26:105
t(8;12;14) in ALL (L3), 28:145
t(8;13) in salivary gland tumors, 24:205
t(8;14) in lymphoma, 24:271
t(8;16) in AML (M2), 24:243
t(8;16) in AMoL (M5a), 24:213
t(8;16) in M4, 27:101
t(8;19) in CML, 25:75
t(8;21) in AML, 25:329
t(8;21) in ANLL, 24:137
t(8;21) in CML, 25:103
t(8;21) in dysplastic nevus syndrome
(DNS), 24:38
t(8;21) in refractory anemia with excess
of blasts, 25:175
t(9;5;22) masked Ph, 26:105
t(9;9;22;11) in Ph translocation, 24:281
t(9;10) with inv(16) and M5b, 26:309
t(9;11) in CML, 25:75, 267
t(9;11) in meningioma, 26:127
t(9;12;22) atypical Ph, 25:183
t(9;12;22) in CML, 24:359
t(9;13) in CLL, 24:145
t(9;13;22) in CML, 24:145
t(9;17) in dysplastic nevus syndrome
(DNS), 24:39
t(9;22) in MDS, 26:213
t(9;22) masked Ph, 26:105
t(10;11) in M5, 26:351
t(10;13) in CLL, 24:145
t(11;11) in breast cancer, 27:293
t(11;12) constitutional in MPD, 24:345
t(11;13) in CLL, 25:109
t(11;14) in CLL, 24:145
t(11;16) in MDS, 27:243
t(11;17) in breast cancer, 27:291
t(11;20) in myeloma, 25:375
t(11;21) in MDS, 27:42
t(11;22) in esthesioneuroblastoma,
29:155
t(11;22) in peripheral neuorepithelioma,
24:119
t(11;22) in primary marrow disease,
28:377
t(12;9;22) variant Ph, 26:105
t(12;11) in hairy cell leukemia, 24:113
t(12;16) in myxoid liposarcoma, 26:185
t(12;21) in dysplastic nevus syndrome
(DNS), 24:39
t(12;22) in CML, 25:183
t(13;14) constitutional in MDS, ALL,
ANLL, 24:345
t(13;15) in MPD, 24:154
t(13;15) Robertsonian (acquired) in PLL,
25:293
t(13;17) in CLL, 24:145
t(13;19) in CLL, 25:109
t(13;22) in CLL, 24:145
t(14;14) and fragile sites, 26:95
t(14;14) in AT, 26:217
t(14;18) in lymphoma, 25:55, 219, 223;
27:339
t(14;18) in myeloma, 25:375
t(14;21) constitutional in ANLL, 24:345
t(15;16) in dysplastic nevus syndrome,
24:39
t(15;17) in APL, 28:113
t(15;17) variant in APL in CML, 28:349
t(15;20) in adrenal cancer, 26:271
t(15;21) in MDS, 27:42
t(15;21) Robertsonian in CML, 25:335
t(16;17) in CLL, 25:109
t(16;18) in PV, 25:238
t(16;21) in CLL, 25:109
t(17;18) in CML, 25:75, 267
t(17;19) in CML, 25:75
t(18;22) in meningioma, 27:145
t(20;22) in CML, 25:183
t(X;13) in CLL, 24:145
t(X;15) in APL, 29:65
t(X;18) in synovial sarcoma, 26:179;
29:179
t(Y;9) in CML, 25:75
t(Y;15) constitutional in MPD, 24:345
t(Y;17) constitutional in MDS, 24:345
tandem in mouse melanoma,
29:81

- Transplantation
 marrow in CML, 26:5
- Trisomy
 origin of +12 in CLL, 28:185
 +4 in ANLL, 26:117, 171, 175
 +7 in malignant fibrous histiocytoma, 29:97
 +8 in refractory anemia, 24:159
 +8, +8 in ANLL, 27:269
 +8, +9 in PV, 25:233
 +9 and thrombocytosis, 27:73
 +9 in hematologic disorders, 27:73
- Trophoblasts
 cytogenetics, 29:271
 from complete moles, 29:271
- Tumors
 brain, 24:163; 26:127
 breast, 24:45
 carcinoid, 24:17
 cytogenetics, 26:177
 gastric, 24:63
 gliomas, 24:163
 lipogenic with ring, 24:327
 meningioma, 26:127
 mitotic recombination in, 27:5
 neuroectodermal, 24:75
 ovarian, 24:231; 26:327; 355
 polyclonal origin, 27:5
 salivary glands (mixed), 24:205; 28:237
 Second International Workshop, 27:1-47
 sex chromosome disorders, 25:191
 transplantable melanoma, 25:123
 urologic, 24:185, 189
- Ureter
 transitional cell carcinoma, 25:369
 tumor with +7 and i(5p), 25:369
- Urologic cancer
 embryonal origin of tumors, 24:189
 supernumerary nipples, 24:185
- Virus
 Abelson induced lymphoma in mouse lines, 28:119
 Simian virus 40, 25:149
 transformation of amniocyte cell lines, 25:149
- Von Hippel-Lindau disease
 renal cell carcinoma, 27:345
 3p- in renal cancer, 27:345
- Waldenström's macroglobulinemia
 chromosome changes, 29:261
- Wilms' tumor
 abnormal #1 in sperm of treated patients, 29:91
 constitutional "hot spot" in sperm of patient with, 29:91
- X-chromosome
 anomalies and neoplasia, 25:191
 i dic(X) in MDS, 27:215
 t(X;15) in APL, 29:65
 t(X;18) in synovial sarcoma, 29:179
 XXX constitutional in ANLL, 24:345
 XXY and acute leukemia, 26:375
 XXY and neoplasia, 25:191
 XXY constitutional in MDS, ALL, MPD, 24:345
 45,XO and neoplasia, 25:191
 45,XO constitutional in AA, 24:345
- Y chromosome
 constitutive heterochromatin in CML, 24:295
 heterochromatism in boys with various tumors, 25:351
 inv(16) in XY/XYY with M4, 29:331
 polymorphism in CML, 24:295
 XYY and AML, 24:363
 XYY constitutional in ANLL, ALL and ET, 24:345
 - Y in lymphoma, 25:219
 - Y in meningioma, 26:127

